[{"article_id":84,"discovery_date":"2021-02-25","title":"Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102840. doi: 10.1016&#x2F;j.msard.2021.102840. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Neurofilament heavy (NfH) is a promising biomarker for neuro-axonal damage in Multiple Sclerosis (MS). We compared the performance of high-sensitivity serum-NfH immunoassays, with as aim to investigate the value of serum-NfH as biomarker for MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We measured serum-NfH in 76 MS patients with Simoa (one commercial, one in-house) or Luminex assays. Serum-NfH measured by the immunoassay with greatest sensitivity was related to clinical and radiological outcomes with age and sex-adjusted linear regression analysis, and to biological outcomes cerebrospinal fluid (CSF)-NfH, serum neurofilament light (NfL) and CSF-NfL with Spearman&#39;s correlation analysis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: With the commercial Simoa assay, we obtained 100% serum-NfH detectability (in-house Simoa: 70%, Luminex: 61%), with lowest coefficient of variation (CV) between duplicates of 11%CV (in-house Simoa: 22%CV, Luminex: 30%CV). Serum-NfH quantified with the commercial Simoa assay was associated with disease duration (standardized beta (sβ) &#x3D; 0.28, p &#x3D; 0.034), T2 lesion volume (sβ &#x3D; 0.23, p &#x3D; 0.041), and tended to associate with black hole count (sβ &#x3D; 0.21, p &#x3D; 0.084) but not with Expanded Disease Disability Score (EDSS) or normalized brain volume (all: p&amp;gt;0.10). Furthermore, serum-NfH showed correlations with CSF-NfH (rho &#x3D; 0.27, p &#x3D; 0.018) and serum-NfL (rho&#x3D;0.44, p &amp;lt; 0.001), but not with CSF-NfL.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Serum-NfH can be quantified with high-sensitivity technology. Cross-sectionally, we observed some weak correlations of serum-NfH with MS disease burden parameters, suggesting there might be some utility for serum-NfH as biomarker for MS disease burden.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626430&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2&quot;&gt;33626430&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102840&gt;10.1016&#x2F;j.msard.2021.102840&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626430&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":83,"discovery_date":"2021-02-25","title":"The CYP2R1 Enzyme: Structure, Function, Enzymatic Properties and Genetic Polymorphism","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Pharm Pharm Sci. 2021;24:94-112. doi: 10.18433&#x2F;jpps31305.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Since the discovery of its role in vitamin D metabolism, significant progress has been made in the understanding of gene organisation, protein structure, catalytic function, and genetic polymorphism of cytochrome P450 2R1 (CYP2R1). Located on chromosome 11p15.2, CYP2R1 possesses five exons, unlike most other CYP isoforms that carry nine exons. CYP2R1 crystal structure displays a fold pattern typical of a CYP protein, with 12 a-helices as its structural core, and b-sheets mostly arranged on one side, and the heme buried in the interior part of the protein. Overall, CYP2R1 structure adopts a closed conformation with the B&#39; helix serving as a gate covering the substrate access channel, with the substrate vitamin D3 occupying a position with the side chain pointing toward the heme group. In liver, CYP2R1 25-hydroxylates vitamin D and serves as an important determinant of 25(OH)D level in the tissue and in circulation. While substrate profile has been well studied, inhibitor specificity for CYP2R1 requires further investigation. Both exonic and non-exonic single nucleotide polymorphisms (SNPs) have been reported in CYP2R1, including the CYP2R1*2 carrying Leu99Pro exchange, and a number of non-exonic SNPs with variable functional consequences in gene regulation. A non-exonic SNP, rs10741657, has its causal relationship with diseases established, including that of rickets, ovarian cancer, and multiple sclerosis. The role of other CYP2R1 SNPs in vitamin D deficiency and their causal link to other traits however remain uncertain currently and more studies are warranted to help identify possible physiological mechanisms underlying those complex traits.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626316&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2&quot;&gt;33626316&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.18433&#x2F;jpps31305&gt;10.18433&#x2F;jpps31305&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626316&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":82,"discovery_date":"2021-02-25","title":"The role of language ability in verbal fluency of individuals with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102846. doi: 10.1016&#x2F;j.msard.2021.102846. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: While cognitive deficits in memory and processing speed have been well-documented in individuals with multiple sclerosis (MS), language is largely considered to be intact. Verbal fluency deficits observed in MS are often attributed to impaired processing speed and executive functions rather than language ability. The current study evaluates the contribution of various cognitive factors to verbal fluency including language ability, oral-motor speed, processing speed, and executive functions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We analyzed pre-existing data from seventy-four (74) individuals with MS who completed a battery of neuropsychological tests designed to assess individual ability for various cognitive factors. We conducted linear multiple regression analyses with letter and category verbal fluency as outcome variables and performance on other cognitive domains (e.g., processing speed, executive functioning) as predictors.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Both vocabulary and processing speed predicted letter fluency while only vocabulary predicted category fluency. These findings suggest that the observed verbal fluency deficits in MS may reflect both impaired language ability and processing speed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: We propose that further research on language ability in MS is needed to determine if comprehensive neuropsychological test batteries for persons with MS should include tests of language ability to fully understand the cognitive profile of any given patient. Given the importance of language ability, it may be necessary to conduct a more thorough assessment of language in individuals with MS who experience a deficit in this domain.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626431&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2&quot;&gt;33626431&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102846&gt;10.1016&#x2F;j.msard.2021.102846&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626431&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":81,"discovery_date":"2021-02-25","title":"Idiopathic Intracranial Hypertension and Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 16;50:102829. doi: 10.1016&#x2F;j.msard.2021.102829. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Unexplained elevated intracranial pressure occasionally develops in individuals with Multiple Sclerosis (MS). Visual symptoms and signs are common to both conditions. An awareness of this association is particularly relevant due to the increased incidence of headache in MS and the frequent overlap of symptoms and signs in both conditions.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626432&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2&quot;&gt;33626432&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102829&gt;10.1016&#x2F;j.msard.2021.102829&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626432&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210225020934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":80,"discovery_date":"2021-02-25","title":"A Multifactorial Model of Multiple Sclerosis Gait and its Changes Across Different Disability Levels","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;IEEE Trans Biomed Eng. 2021 Feb 24;PP. doi: 10.1109&#x2F;TBME.2021.3061998. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: Mobility assessment is critical in the clinical management of people with Multiple Sclerosis (pwMS). Instrumented gait analysis provides a plethora of metrics for quantifying concurrent factors contributing to gait deterioration. However, a gait model discriminating underlying features contributing to this deterioration is lacking in pwMS. This study aimed at developing and validating such a model.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The gait of 24 healthy controls and 114 pwMS with mild, moderate, or severe disability was measured with inertial sensors on the shanks and lower trunk while walking for 6 minutes along a hospital corridor. Twenty out of thirty-six initially explored metrics computed from the sensor data met the quality criteria for exploratory factor analysis. This analysis provided the sought model, which underwent a confirmatory factor analysis before being used to characterize gait impairment across the three disability groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: A gait model consisting of five domains (rhythm&#x2F;variability, pace, asymmetry, and forward and lateral dynamic balance) was revealed by the factor analysis, which was able to highlight gait abnormalities across the disability groups: significant alterations in rhythm&#x2F;variability-, asymmetry-, and pace-based features were present in the mild group, but these were more profound in the moderate and severe groups. Deterioration in dynamic balance-based features was only noted in pwMS with a moderate and severe disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: A conceptual model of gait for disease-specific mobility assessment in pwMS was successfully developed and tested.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SIGNIFICANCE: The new model, built with metrics that represent gait impairment in pwMS, highlighted clinically relevant changes across different disability levels, including those with no clinically observable walking disability. This shows the clear potential as a monitoring biomarker in pwMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625975&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224192934&amp;v&#x3D;2.14.2&quot;&gt;33625975&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1109&#x2F;TBME.2021.3061998&gt;10.1109&#x2F;TBME.2021.3061998&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625975&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224192934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":79,"discovery_date":"2021-02-25","title":"Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Acta Neurol Scand. 2021 Feb 24. doi: 10.1111&#x2F;ane.13400. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To identify serum proteins associated with MS and affected by interferon beta treatment.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Plasma samples from 29 untreated relapsing-remitting MS patients and 15 healthy controls were investigated with a multiplexed panel containing 92 proteins related to inflammation. Follow-up samples were available from 13 patients at 1 and 3 months after initiation of treatment with interferon beta-1a.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Ten proteins were differentially expressed in MS patients. Five of these were altered by treatment with IFN-β 1a: uPA, CX3CL1, CCL2, TRAIL and IL18.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: CCL2 and TRAIL were confirmed to be modulated with interferon beta treatment in MS. As novel findings, we now report that uPA and CX3CL1 were differentially expressed in MS and increased after IFN-beta-1a treatment. Conflicting results have been reported on how interferon beta affects IL-18.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626181&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224192934&amp;v&#x3D;2.14.2&quot;&gt;33626181&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ane.13400&gt;10.1111&#x2F;ane.13400&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33626181&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224192934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":78,"discovery_date":"2021-02-25","title":"Leveraging electronic health records data to predict multiple sclerosis disease activity","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Feb 24. doi: 10.1002/acn3.51324. Online ahead of print.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;OBJECTIVE: No relapse risk prediction tool is currently available to guide treatment selection for multiple sclerosis (MS). Leveraging electronic health record (EHR) data readily available at the point of care, we developed a clinical tool for predicting MS relapse risk.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;METHODS: Using data from a clinic-based research registry and linked EHR system between 2006 and 2016, we developed models predicting relapse events from the registry in a training set (n = 1435) and tested the model performance in an independent validation set of MS patients (n = 186). This iterative process identified prior 1-year relapse history as a key predictor of future relapse but ascertaining relapse history through the labor-intensive chart review is impractical. We pursued two-stage algorithm development: (1) L&lt;sub&gt;1&lt;/sub&gt; -regularized logistic regression (LASSO) to phenotype past 1-year relapse status from contemporaneous EHR data, (2) LASSO to predict future 1-year relapse risk using imputed prior 1-year relapse status and other algorithm-selected features.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;RESULTS: The final model, comprising age, disease duration, and imputed prior 1-year relapse history, achieved a predictive AUC and F score of 0.707 and 0.307, respectively. The performance was significantly better than the baseline model (age, sex, race/ethnicity, and disease duration) and noninferior to a model containing actual prior 1-year relapse history. The predicted risk probability declined with disease duration and age.&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;CONCLUSION: Our novel machine-learning algorithm predicts 1-year MS relapse with accuracy comparable to other clinical prediction tools and has applicability at the point of care. This EHR-based two-stage approach of outcome prediction may have application to neurological disease beyond MS.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626237/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224192934&amp;v=2.14.2&quot;&gt;33626237&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1002/acn3.51324&gt;10.1002/acn3.51324&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33626237/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224192934&v=2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":77,"discovery_date":"2021-02-24","title":"Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177&#x2F;1352458521996699. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625275&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2&quot;&gt;33625275&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521996699&gt;10.1177&#x2F;1352458521996699&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625275&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":76,"discovery_date":"2021-02-24","title":"Machine and deep learning in MS research are just powerful statistics - Yes","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458520981309. doi: 10.1177&#x2F;1352458520981309. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625280&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2&quot;&gt;33625280&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458520981309&gt;10.1177&#x2F;1352458520981309&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625280&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":75,"discovery_date":"2021-02-24","title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Manag Care Spec Pharm. 2021 Feb 24:1-11. doi: 10.18553&#x2F;jmcp.2021.20413. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;BACKGROUND:&lt;&#x2F;b&gt; Ocrelizumab (OCR) is the only disease-modifying therapy (DMT) for both relapsing and primary progressive forms of multiple sclerosis (MS). OCR is given by intravenous (IV) infusion twice a year, which may improve adherence to the dosing schedule relative to other MS DMTs that require more frequent administration. Real-world evidence on the persistence and adherence of patients with MS to OCR compared with other DMTs is limited. &lt;b&gt;OBJECTIVE:&lt;&#x2F;b&gt; To examine the persistence and adherence to OCR compared with other DMTs for MS in the United States. &lt;b&gt;METHODS:&lt;&#x2F;b&gt; This analysis was conducted in the PharMetrics Plus commercial claims database and included patients with MS who initiated a new DMT between April 2017 and September 2018. Patients were required to have health plan enrollment for ≥ 1 year before and after DMT initiation (a subgroup analysis was performed for those with ≥ 18 months&#39; continuous enrollment after DMT initiation). Persistence was defined as not switching to another DMT and having no gap in coverage of the initiated DMT for ≥ 60 days during the postinitiation period. The proportion of days covered (PDC) was calculated as the total days covered by the DMT during the postinitiation period divided by the length of the time period (12 or 18 months); PDC ≥ 0.8 was considered adherent. Multivariable Poisson regression models compared discontinuation (nonpersistence) and nonadherence between OCR users and users of other DMTs grouped by administration route. &lt;b&gt;RESULTS:&lt;&#x2F;b&gt; A total of 4,587 patients (OCR, 1,319; injectable, 1,051; oral, 1,876; other IV, 341) were included. The OCR group had the lowest proportion of patients discontinuing at 12 months (8% vs. 28%, 32%, and 43% for other IV, oral, and injectable, respectively) and the highest mean PDC (93% vs. 76%, 74%, and 69%, respectively). Compared with patients initiating OCR, adjusted relative risks (RR) of 12-month discontinuation were 3.3 (95% CI &#x3D; 2.3-4.6), 3.8 (95% CI &#x3D; 3.0-4.9), and 5.5 (95% CI &#x3D; 4.1-7.5) for patients initiating other IV, oral, and injectable DMTs, respectively. Similarly, patients initiating other IV, oral, and injectable DMTs had RRs of 4.9 (95% CI &#x3D; 3.6-6.8), 5.1 (95% CI &#x3D; 3.9-6.6), and 6.8 (95% CI &#x3D; 5.0-9.3) for 12-month nonadherence compared with OCR. A subgroup of 2,913 patients with 18 months of continuous enrollment had similar trends, with 17% in the OCR group discontinuing compared with 40%, 41%, and 55% in the other IV, oral, and injectable groups, respectively. Trends over 18 months were consistent with the 12-month analysis in adjusted models. &lt;b&gt;CONCLUSIONS:&lt;&#x2F;b&gt; Patients initiating OCR had superior persistence and adherence at 12 and 18 months of follow-up compared with patients initiating other MS DMTs. Long-term persistence and adherence should be monitored as OCR experience accrues in a real-world setting. &lt;b&gt;DISCLOSURES:&lt;&#x2F;b&gt; This study was funded by Genentech (South San Francisco, CA), a member of the Roche Group. Engmann, Sheinson, Bawa, and Ng are employees of Genentech and shareholders of F. Hoffman-La Roche (Basel, Switzerland).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624535&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2&quot;&gt;33624535&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.18553&#x2F;jmcp.2021.20413&gt;10.18553&#x2F;jmcp.2021.20413&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624535&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":74,"discovery_date":"2021-02-24","title":"A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease-modifying or symptom-alleviating multiple sclerosis drugs","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Phytother Res. 2021 Feb 24. doi: 10.1002&#x2F;ptr.7050. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple Sclerosis (MS) is a demyelinating disease affecting the central nervous system, with no curative medicine available. The use of herbal drugs and dietary supplements is increasing among people with MS (PwMS), raising a need for knowledge about potential interactions between conventional MS medicine and herbal drugs&#x2F;dietary supplements. This systematic review provides information about the safety of simultaneous use of conventional MS-drugs and herbal drugs frequently used by PwMS. The study included 14 selected disease-modifying treatments and drugs frequently used for symptom-alleviation. A total of 129 published papers found via PubMed and Web of Science were reviewed according to defined inclusion- and exclusion criteria. Findings suggested that daily recommended doses of Panax ginseng and Ginkgo biloba should not be exceeded, and herbal preparations differing from standardized products should be avoided, especially when combined with anticoagulants or substrates of certain cytochrome P450 isoforms. Further studies are required regarding ginseng&#39;s ability to increase aspirin bioavailability. Combinations between chronic cannabis use and selective serotonin reuptake inhibitors or non-steroidal antiinflammatory drugs should be carefully monitored, whereas no significant evidence for drug-interactions between conventional MS-drugs and ginger, cranberry, vitamin D, fatty acids, turmeric, probiotics or glucosamine was found.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2&quot;&gt;33624893&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;ptr.7050&gt;10.1002&#x2F;ptr.7050&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624893&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":73,"discovery_date":"2021-02-24","title":"Machine and deep learning in MS research are just powerful statistics - No","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 24:1352458520978648. doi: 10.1177&#x2F;1352458520978648. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625302&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2&quot;&gt;33625302&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458520978648&gt;10.1177&#x2F;1352458520978648&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625302&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":72,"discovery_date":"2021-02-24","title":"Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Cell Mol Neurobiol. 2021 Feb 24. doi: 10.1007&#x2F;s10571-021-01059-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Antibodies and oxidative stress are hallmarks of multiple sclerosis (MS) lesions. We aimed to clarify the relation between them, their role in MS patients and to investigate their specificity, comparing MS with classical neurodegenerative diseases (ND). Brain samples from 14 MS cases, 6 with ND and 9 controls (without neurological diseases). Immunohistochemistry assays were used to detect oxidized lipids (EO6), IgG and IgM, oligodendrocytes (Olig2), axons (NF, neurofilament) and cellular (TUNEL) and axonal damage (APP, amyloid precursor protein). We did not observe EO6 in controls. All samples from MS patients showed EO6 in oligodendrocytes and axons within lesions. We did not detect co-localization between EO6 and antibodies. Neither did we between EO6 and TUNEL or APP. 94.4% of TUNEL-positive cells in normal appearing white matter were also stained for IgG and 75.5% for IgM. IgM, but not IgG, co-localized with APP. EO6 was associated with axonal damage in amyotrophic lateral sclerosis (ALS). We did not observe association between antibodies and cellular or axonal damage in ND patients. MS patients showed a higher number of B cells and plasma cells in the lesions and meninges than controls. The number of B cells and plasma cells was associated with the presence of antibodies and with the activity of the lesions. We observed a main role of B lymphocytes in the development of MS lesions. Antibodies contribute to the oligodendrocyte and axonal damage in MS. Oxidative stress was associated with axonal damage in ALS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625628&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2&quot;&gt;33625628&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10571-021-01059-6&gt;10.1007&#x2F;s10571-021-01059-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33625628&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224152934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":71,"discovery_date":"2021-02-24","title":"Single-cell immune repertoire and transcriptome sequencing reveals that clonally expanded and transcriptionally distinct lymphocytes populate the aged central nervous system in mice","summary":"&lt;div&gt;&lt;p style=&quot;color: #4aa564;&quot;&gt;Proc Biol Sci. 2021 Feb 24;288(1945):20202793. doi: 10.1098/rspb.2020.2793. Epub 2021 Feb 24.&lt;/p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;/b&gt;&lt;/p&gt;&lt;p xmlns:xlink=&quot;http://www.w3.org/1999/xlink&quot; xmlns:mml=&quot;http://www.w3.org/1998/Math/MathML&quot; xmlns:p1=&quot;http://pubmed.gov/pub-one&quot;&gt;Neuroinflammation plays a crucial role during ageing and various neurological conditions, including Alzheimer&#x27;s disease, multiple sclerosis and infection. Technical limitations, however, have prevented an integrative analysis of how lymphocyte immune receptor repertoires and their accompanying transcriptional states change with age in the central nervous system. Here, we leveraged single-cell sequencing to simultaneously profile B cell receptor and T cell receptor repertoires and accompanying gene expression profiles in young and old mouse brains. We observed the presence of clonally expanded B and T cells in the central nervous system of aged male mice. Furthermore, many of these B cells were of the IgM and IgD isotypes, and had low levels of somatic hypermutation. Integrating gene expression information additionally revealed distinct transcriptional profiles of these clonally expanded lymphocytes. Our findings implicate that clonally related T and B cells in the CNS of elderly mice may contribute to neuroinflammation accompanying homeostatic ageing.&lt;/p&gt;&lt;p style=&quot;color: lightgray&quot;&gt;PMID:&lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33622131/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210224100934&amp;v=2.14.2&quot;&gt;33622131&lt;/a&gt; | DOI:&lt;a href=https://doi.org/10.1098/rspb.2020.2793&gt;10.1098/rspb.2020.2793&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;","link":"https://pubmed.ncbi.nlm.nih.gov/33622131/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210224100934&v=2.14.2","published_date":"","source":"pubmed","relevant":"","table_constraints":null},{"article_id":70,"discovery_date":"2021-02-24","title":"Effects of diminished positive mood and depressed mood upon verbal learning and memory among people with multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Clin Exp Neuropsychol. 2021 Feb 23:1-12. doi: 10.1080&#x2F;13803395.2020.1853066. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Objective&lt;&#x2F;b&gt;: Cognitive impairment affects as many as 65% of people with multiple sclerosis (PWMS), and memory impairment confers greater severity of disability and functional impairment. Depression is also common among PWMS, and lifetime prevalence rates are as high as 50%. Research has yet to clearly define the relationship between memory dysfunction and depression among PWMS, and may reflect incomplete assessment of depressive symptoms. The present study examined different aspects of depressive symptoms including anhedonia (i.e., diminished positive mood) and their relationships with verbal learning and memory among PWMS.&lt;b&gt;Method&lt;&#x2F;b&gt;: Participants were 48 healthy individuals and 96 PWMS. They were primarily Caucasian (90.3%) and female (75.0%). Participants completed the California Verbal Learning Test-2 (CVLT-2) to assess verbal learning and memory and the Chicago Multiscale Depression inventory to assess depressed mood (CMDI-Mood) and diminished positive mood (CMDI-DPM).&lt;b&gt;Results&lt;&#x2F;b&gt;: Linear regression revealed that the main effect of CMDI-DPM and the interaction of CMDI-DPM and CMDI-Mood significantly explained variance across learning, recall, and recognition CVLT-2 indices. Follow-up analyses indicated that CMDI-DPM was only significant in the absence of high CMDI-Mood scores. CMDI-Mood explained variance in only CVLT-2 Trial B.&lt;b&gt;Conclusions&lt;&#x2F;b&gt;: Depressed mood had little direct effect upon memory performance in PWMS. In the absence of severe depressed mood, higher levels of positive mood corresponded to better memory performance. However, the impact of diminished positive mood was rendered null among those endorsing high levels of depressed mood. These data may imply that anhedonia corresponds with poorer memory function among PWMS, and suggests that investigators and clinicians should assess multiple mood dimensions among PWMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33622171&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33622171&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;13803395.2020.1853066&gt;10.1080&#x2F;13803395.2020.1853066&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33622171&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":69,"discovery_date":"2021-02-24","title":"Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(3):e964. doi: 10.1212&#x2F;NXI.0000000000000964. Print 2021 May.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To examine whether treatment with epigallocatechin gallate (EGCG) influences progression of brain atrophy, reduces clinical and further radiologic disease activity markers, and is safe in patients with progressive multiple sclerosis (PMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We enrolled 61 patients with primary or secondary PMS in a randomized double-blind, parallel-group, phase II trial on oral EGCG (up to 1,200 mg daily) or placebo for 36 months with an optional open-label EGCG treatment extension (OE) of 12-month duration. The primary end point was the rate of brain atrophy, quantified as brain parenchymal fraction (BPF). The secondary end points were radiologic and clinical disease parameters and safety assessments.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In our cohort, 30 patients were randomized to EGCG treatment and 31 to placebo. Thirty-eight patients (19 from each group) completed the study. The primary endpoint was not met, as in 36 months the rate of decrease in BPF was 0.0092 ± 0.0152 in the treatment group and -0.0078 ± 0.0159 in placebo-treated patients. None of the secondary MRI and clinical end points revealed group differences. Adverse events of EGCG were mostly mild and occurred with a similar incidence in the placebo group. One patient in the EGCG group had to stop treatment due to elevated aminotransferases (&amp;gt;3.5 times above normal limit).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: In a phase II trial including patients with multiple sclerosis (MS) with progressive disease course, we were unable to demonstrate a treatment effect of EGCG on the primary and secondary radiologic and clinical disease parameters while confirming on overall beneficial safety profile.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLINICALTRIALGOV IDENTIFIER: NCT00799890.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This phase II trial provides Class II evidence that for patients with PMS, EGCG was safe, well tolerated, and did not significantly reduce the rate of brain atrophy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33622766&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33622766&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;NXI.0000000000000964&gt;10.1212&#x2F;NXI.0000000000000964&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33622766&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":68,"discovery_date":"2021-02-24","title":"Correlation of Dietary Intake and Helicobacter pylori Infection with Multiple Sclerosis, a Case-Control Study in Rafsanjan, Iran, 2017-18","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Qatar Med J. 2021 Feb 5;2020(3):45. doi: 10.5339&#x2F;qmj.2020.45. eCollection 2020.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Some environmental factors, such as &lt;i&gt;Helicobacter pylori&lt;&#x2F;i&gt; infection (HPI), are likely to be considered a protective factor in MS. Dietary intake may provide exposure to or have protective effects for MS. The present study aimed to determine the relationship between serum anti-H. pylori IgG antibody (HPIA) level and dietary intake in patients with MS referred to the MS Clinic in Rafsanjan city, Iran.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: The present case-control study was conducted on 97 patients with MS and 95 controls. The two groups had no significant difference in age and gender (&lt;i&gt;p&lt;&#x2F;i&gt; &amp;gt; 0.05). HPIA was checked, and the food frequency questionnaire was completed in both groups to measure nutritional intake. All data were analyzed by the SPSS 20 software using independent t-test, Chi-Square, Mann-Whitney U test, and correlation.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The median serum HPIA level was significantly lower in MS cases than in controls. Furthermore, the median consumption of glutamic acid, arginine, serine, aspartic acid, alanine, proline, and caffeine was significantly lower in MS cases than in controls. A significant positive correlation was found between the levels of linoleic acid, lactose, Ca, molybdenum, galactose, leucine, and valine, and the level of HPIA in controls.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Our study results demonstrated that some dietary nutrients had correlations with MS and HPI. Therefore, professionals from multiple disciplines must find which foods contain these dietary nutrients in future studies.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623753&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33623753&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7878158&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;PMC7878158&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.5339&#x2F;qmj.2020.45&gt;10.5339&#x2F;qmj.2020.45&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623753&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":67,"discovery_date":"2021-02-24","title":"Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neural Transm (Vienna). 2021 Feb 23. doi: 10.1007&#x2F;s00702-021-02306-2. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The aim of the current review was to provide a new, in-depth insight into possible pharmacological targets of amantadine to pave the way to extending its therapeutic use to further indications beyond Parkinson&#39;s disease symptoms and viral infections. Considering amantadine&#39;s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Further three targets could play a role to a lesser extent: NMDA receptors, 5-HT3 receptors, and potassium channels. Based on published clinical studies, traumatic brain injury, fatigue [e.g., in multiple sclerosis (MS)], and chorea in Huntington&#39;s disease should be regarded potential, encouraging indications. Preclinical investigations suggest amantadine&#39;s therapeutic potential in several further indications such as: depression, recovery after spinal cord injury, neuroprotection in MS, and cutaneous pain. Query in the database http:&#x2F;&#x2F;www.clinicaltrials.gov reveals research interest in several further indications: cancer, autism, cocaine abuse, MS, diabetes, attention deficit-hyperactivity disorder, obesity, and schizophrenia.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624170&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33624170&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00702-021-02306-2&gt;10.1007&#x2F;s00702-021-02306-2&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624170&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":66,"discovery_date":"2021-02-24","title":"Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Sci Sleep. 2021 Feb 16;13:201-207. doi: 10.2147&#x2F;NSS.S256676. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The prevalence of sleep disorders in individuals with multiple sclerosis (MS) is 3-5 times higher compared to the general population. Insomnia Disorder, defined as difficulty falling asleep, maintaining sleep or waking up too early, can lead to significant fatigue, the most common and disabling symptom of MS. In addition, fatigue and insomnia in patients with MS also can overlap with and exacerbate other psychological and physical symptoms. Cognitive behavioral therapy for insomnia (CBT-I) has been shown as an effective treatment for chronic insomnia and burgeoning research has demonstrated the effectiveness of this treatment for insomnia in individuals with a variety of comorbid medical conditions including MS. The purpose of the current review will explore the literature surrounding the prevalence and impact of sleep disorders and fatigue in MS. Additionally, this review will address practical ways to help individuals with MS manage fatigue as well as how to modify typical standard behavioral treatments for insomnia to take into account special considerations for individuals with MS based on the level of disability and other comorbid issues that impact sleep.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623461&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33623461&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7896778&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;PMC7896778&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2147&#x2F;NSS.S256676&gt;10.2147&#x2F;NSS.S256676&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623461&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":65,"discovery_date":"2021-02-24","title":"Inflammaging markers characteristic of advanced age show similar levels with frailty and dependency","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 23;11(1):4358. doi: 10.1038&#x2F;s41598-021-83991-7.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The improvement of life quality and medical advances has resulted in increased life expectancy. Despite this, health status commonly worsens in the last years of life. Frailty is an intermediate and reversible state that often precedes dependency and therefore, its identification may be essential to prevent dependency. However, there is no consensus on the best tools to identify frailty. In this sense, diverse molecules have been proposed as potential biomarkers. Some investigations pointed to an increased chronic inflammation or inflammaging with frailty, while others did not report such differences. In this work, we evaluated the circulating concentration of the inflammaging markers in adults and older adults (aged over 70 years) by ELISA and Luminex techniques. The Barthel Index was applied for the evaluation of dependency and Timed up-and-go, Gait Speed, Short Physical Performance Battery, Tilburg Frailty Indicator and Gerontopole Frailty Screening Tool were used for the identification of frailty. CRP, TNF-α, IL-6 and albumin concentrations were measured, and we found that elevated inflammation is present in older adults, while no differences with frailty and dependency were reported. Our results were consistent for all the evaluated frailty scales, highlighting the need to reconsider increased inflammation as a biomarker of frailty.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623057&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33623057&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41598-021-83991-7&gt;10.1038&#x2F;s41598-021-83991-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623057&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":64,"discovery_date":"2021-02-24","title":"Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler J Exp Transl Clin. 2021 Feb 8;7(1):2055217321992394. doi: 10.1177&#x2F;2055217321992394. eCollection 2021 Jan-Mar.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: To identify Magnetic Resonance Imaging (MRI), clinical and demographic biomarkers predictive of worsening information processing speed (IPS) as measured by Symbol Digit Modalities Test (SDMT).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Demographic, clinical data and 1.5 T MRI scans were collected in 76 patients at time of inclusion, and after 5 and 10 years. Global and tissue-specific volumes were calculated at each time point. For the primary outcome of analysis, SDMT was used.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Worsening SDMT at 5-year follow-up was predicted by baseline age, Expanded Disability Status Scale (EDSS), SDMT, whole brain volume (WBV) and T2 lesion volume (LV), explaining 30.2% of the variance of SDMT. At 10-year follow-up, age, EDSS, grey matter volume (GMV) and T1 LV explained 39.4% of the variance of SDMT change.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: This longitudinal study shows that baseline MRI-markers, demographic and clinical data can help predict worsening IPS. Identification of patients at risk of IPS decline is of importance as follow-up, treatment and rehabilitation can be optimized.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33623706&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7876764&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;PMC7876764&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2055217321992394&gt;10.1177&#x2F;2055217321992394&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33623706&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":63,"discovery_date":"2021-02-24","title":"Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Hum Brain Mapp. 2021 Feb 24. doi: 10.1002&#x2F;hbm.25375. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;There is evidence that multiple sclerosis (MS) pathology leads to distinct patterns of volume loss over time (VLOT) in different central nervous system (CNS) structures. We aimed to use such patterns to identify patient subgroups. MS patients of all classical disease phenotypes underwent annual clinical, blood, and MRI examinations over 6 years. Spinal, striatal, pallidal, thalamic, cortical, white matter, and T2-weighted lesion volumes as well as serum neurofilament light chain (sNfL) were quantified. CNS VLOT patterns were identified using principal component analysis and patients were classified using hierarchical cluster analysis. 225 MS patients were classified into four distinct Groups A, B, C, and D including 14, 59, 141, and 11 patients, respectively). These groups did not differ in baseline demographics, disease duration, disease phenotype distribution, and lesion-load expansion. Interestingly, Group A showed pronounced spinothalamic VLOT, Group B marked pallidal VLOT, Group C small between-structure VLOT differences, and Group D myelocortical volume increase and pronounced white matter VLOT. Neurologic deficits were more severe and progressed faster in Group A that also had higher mean sNfL levels than all other groups. Group B experienced more frequent relapses than Group C. In conclusion, there are distinct patterns of VLOT across the CNS in MS patients, which do not overlap with clinical MS subtypes and are independent of disease duration and lesion-load but are partially associated to sNfL levels, relapse rates, and clinical worsening. Our findings support the need for a more biologic classification of MS subtypes including volumetric and body-fluid markers.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624390&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2&quot;&gt;33624390&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;hbm.25375&gt;10.1002&#x2F;hbm.25375&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33624390&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224100934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":62,"discovery_date":"2021-02-24","title":"miRNA-467b inhibits Th17 differentiation by targeting eIF4E in experimental autoimmune encephalomyelitis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mol Immunol. 2021 Feb 20;133:23-33. doi: 10.1016&#x2F;j.molimm.2021.02.008. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) are neuroinflammatory autoimmune diseases characterized by the axonal loss, demyelination, and neurodegeneration of the central nervous system. Overactivation of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; T cells, especially the migration of the Th1 and Th17 subsets into the central nervous system (CNS), leads to the secretion of inflammatory mediators and destruction of the contact between neurons and activated macrophages, which can then result in a series of neurocognitive and motor deficits. In this study, we intended to explore the role of miRNA-467b in regulating Th cell development in EAE. We found that the level of miRNA-467b was decreased and eukaryotic initiation factor 4 F (eIF4E) was increased in lymph nodes and the CNS at EAE peak. eIF4E was confirmed as the direct target of miRNA467b. Overexpression of miRNA-467b could suppress a percentage of CD4&lt;sup&gt;+&lt;&#x2F;sup&gt; IL-17&lt;sup&gt;+&lt;&#x2F;sup&gt; cells in EAE CD4 + T cells in vitro. In addition, we also identified miRNA-467b, which could suppress Th17 cell differentiation by targeting eIF4E in vitro. Furthermore, injecting miRNA-467b mimics into the caudal vein of EAE mice contributed to less inflammation in the peripheral lymphoid organs and CNS and alleviated disease severity. Taken together, our findings imply that miRNA-467b inhibits the differentiation and function of Th17 cells by targeting eIF4E, thereby alleviating EAE.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621940&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224012934&amp;v&#x3D;2.14.2&quot;&gt;33621940&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.molimm.2021.02.008&gt;10.1016&#x2F;j.molimm.2021.02.008&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621940&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224012934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":1,"table_constraints":null},{"article_id":61,"discovery_date":"2021-02-24","title":"Is maximal muscle strength and fatigability of three lower limb muscle groups associated with walking capacity and fatigability in multiple sclerosis? An exploratory study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102841. doi: 10.1016&#x2F;j.msard.2021.102841. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Both muscle fatigability and walking fatigability are prevalent in persons with MS (pwMS), but their associations remains unclear. The aim of this study was to examine the association of muscle strength and fatigability from both isometric and concentric protocols of three different muscle groups, and their association to walking capacity and walking fatigability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Twenty-seven pwMS and 13 Healthy Controls (HC) were included in this exploratory study. All participants performed a six-minute walking test (6MWT), where the distance walked index (DWI) was calculated to measure walking fatigability with a cut-off score of -10%. In three different muscle groups (knee extensors (KE), knee flexors (KF), ankle dorsiflexors (DF)), isometric and concentric muscle fatigability protocols (FI&lt;sub&gt;isometric&lt;&#x2F;sub&gt; or FI&lt;sub&gt;concentric&lt;&#x2F;sub&gt;) were used to quantify maximal voluntary contraction (MVC) and muscle fatigability. Pearson or Spearman correlation coefficients and linear regression models were calculated to establish the association between muscle strength&#x2F;fatigability and walking capacity&#x2F;fatigability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Higher MVCs values for all muscle groups were found in HC compared to pwMS (mainly those having walking fatigability) (p &amp;lt; 0.05). FI&lt;sub&gt;isometric&lt;&#x2F;sub&gt; of DF was lower in pwMS having walking fatigability compared to no walking fatigability. MVC of KE, KF and DF had a low to moderate association with walking capacity (range r &#x3D; 0.52-0.56; p &amp;lt; 0.05) and walking fatigability in pwMS (range r-r&lt;sub&gt;s&lt;&#x2F;sub&gt;: 0.39-0.50; p&amp;lt;0.05). FI&lt;sub&gt;concentric&lt;&#x2F;sub&gt; of KF and DF, but not of KE, were associated with walking fatigability (r &#x3D; 0.39 and r&lt;sub&gt;s&lt;&#x2F;sub&gt; &#x3D; 0.47, respectively; p &amp;lt; 0.05). In contrast, FI&lt;sub&gt;isometric&lt;&#x2F;sub&gt; for all muscle groups were not related to walking capacity or walking fatigability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: MVC of KE, KF and DF are associated with walking capacity and walking fatigability, while concentric (but not isometric) muscle fatigability of KF and DF are associated with walking fatigability.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621946&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224012934&amp;v&#x3D;2.14.2&quot;&gt;33621946&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102841&gt;10.1016&#x2F;j.msard.2021.102841&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621946&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210224012934&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":60,"discovery_date":"2021-02-24","title":"Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Radiology. 2021 Feb 23:203071. doi: 10.1148&#x2F;radiol.2021203071. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Susceptibility-weighted imaging (SWI) evolved from simple two-dimensional T2*-weighted sequences to three-dimensional sequences with improved spatial resolution and enhanced susceptibility contrast. SWI is an MRI sequence sensitive to compounds that distort the local magnetic field (eg, calcium and iron), in which the phase information can differentiate. But the term &lt;i&gt;SWI&lt;&#x2F;i&gt; is colloquially used to denote high-spatial-resolution susceptibility-enhanced sequences across different MRI vendors and sequences even when phase information is not used. The imaging appearance of SWI and related sequences strongly depends on the acquisition technique. Initially, SWI and related sequences were mostly used to improve the depiction of findings already known from standard two-dimensional T2*-weighted neuroimaging: more microbleeds in patients who are aging or with dementia or mild brain trauma; increased conspicuity of superficial siderosis in Alzheimer disease and amyloid angiopathy; and iron deposition in neurodegenerative diseases or abnormal vascular structures, such as capillary telangiectasia. But SWI also helps to identify findings not visible on standard T2*-weighted images: the nigrosome 1 in Parkinson disease and dementia with Lewy bodies, the central vein and peripheral rim signs in multiple sclerosis, the peripheral rim sign in abscesses, arterial signal loss related to thrombus, asymmetrically prominent cortical veins in stroke, and intratumoral susceptibility signals in brain neoplasms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620291&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2&quot;&gt;33620291&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1148&#x2F;radiol.2021203071&gt;10.1148&#x2F;radiol.2021203071&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620291&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":59,"discovery_date":"2021-02-24","title":"The impact of neurological disability and sensory loss on mindfulness practice","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Disabil Rehabil. 2021 Feb 23:1-9. doi: 10.1080&#x2F;09638288.2021.1887946. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVES: Mindfulness-based approaches are increasingly recommended in the management of medical conditions associated with sensory loss and absence, such as Spinal Cord Injury (SCI), Multiple Sclerosis (MS) and Functional Neurological Disorder (FND). Yet the implications of undertaking practices such as body scanning when living with sensory loss have not been considered. This study aimed to explore the impact of sensory loss on the practice and experience of mindfulness in qualified mindfulness teachers with SCI&#x2F;FND&#x2F;MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Eight mindfulness teachers (5 females, 3 males) with SCI&#x2F;FND&#x2F;MS, sensory loss and wheelchair use were recruited from mindfulness teacher databases. In-depth, semi-structured interviews were undertaken, lasting between 50 and 93 min. Interviews were transcribed verbatim and analysed using Interpretative Phenomenological Analysis. Idiographic analyses for descriptive, linguistic and conceptual themes were completed before cross-case analyses.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Analyses resulted in two superordinate themes: (1) Adopting your Body; and (2) Sensation without Loss. These themes reflected the challenge of overcoming initial resistance to areas of the body with sensory disruption, building a relationship with the whole body, such that sensory awareness could be visualised and experienced without proprioception.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Mindfulness offers a unique approach to accepting and working with the body after paralysis or sensory loss. Fundamental to the use of mindfulness with such populations, is the prioritisation of inclusive sensory language and exploring sensory absence as well as sensory presence. The cognitive and emotional outcomes of body scanning may be uniquely elevated in populations with neurophysiological disorders, highlighting the benefits of mindfulness for adaptive and protective self-management.IMPLICATIONS FOR REHABILITATIONMindfulness-based practices which focus on the body and sensation are accessible to people with neurological limitations.Mindfulness techniques can be extended through the use of visualisation strategies to encourage (non-proprioceptive) awareness of paralysed limbs or areas of the body with sensory loss.The language used in mindfulness-based interventions may need adapted by practitioners so that it remains inclusive for people with sensory loss as well as sensory presence.Additional care needs to be taken when using body scans during mindfulness as they have the potential to exacerbate psychological distress in people with reduced sensory awareness.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621135&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2&quot;&gt;33621135&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;09638288.2021.1887946&gt;10.1080&#x2F;09638288.2021.1887946&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621135&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":58,"discovery_date":"2021-02-24","title":"Efficacy classification of modern therapies in multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Comp Eff Res. 2021 Feb 23. doi: 10.2217&#x2F;cer-2020-0267. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. &lt;b&gt;Materials &amp;amp; methods:&lt;&#x2F;b&gt; Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. &lt;b&gt;Results:&lt;&#x2F;b&gt; For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. &lt;b&gt;Conclusion:&lt;&#x2F;b&gt; Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620251&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2&quot;&gt;33620251&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2217&#x2F;cer-2020-0267&gt;10.2217&#x2F;cer-2020-0267&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620251&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":57,"discovery_date":"2021-02-24","title":"The effect of pelvic floor exercise program on incontinence and sexual dysfunction in multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Int Urol Nephrol. 2021 Feb 23. doi: 10.1007&#x2F;s11255-021-02804-y. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: Multiple sclerosis (MS) is a chronic neuroinflammatory disease of the central nervous system that involves different neurological areas. In addition to lower urinary tract symptoms (LUTS), sexual dysfunction (SD), and psychopathological effects, MS sometimes seriously impairs the quality of life (QoL). We hypothesize that the pelvic floor exercise program (PFEP) could improve bladder, sexual function, depression, and QoL in MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Patients diagnosed with MS completed the Incontinence Questionnaire Short Form (ICIQ-SF), the Beck Depression Inventory (BDI), the Multiple Sclerosis Quality of Life-54 (MSQoL-54) questionnaire, and either the Female Sexual Function Index (FSFI) or the Sexual Health Inventory for Men (SHIM). Maximum bladder volumes (MBV) and post-voiding residual (PVR) volumes were measured using ultrasonography. The patients who regularly completed the PFEP for 12 weeks were asked to fill out the questionnaires again, and their MBV and PVR were remeasured.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Seventy-two patients with relapsing-remitting multiple sclerosis (RRMS) were included in the study. Forty-two (58.3%) RRMS patients reached the end of the study. The patients&#39; post-PFEP average MBV statistically increased (p &#x3D; 0.01). In contrast, no statistically significant difference was found in the PVR (p &#x3D; 0.2). After exercise, the FSFI values in women increased (p &#x3D; 0.02), and ICIQ-SF and BDI values in all the RRMS patients statistically decreased (p &#x3D; 0.004, p &#x3D; 0.01, respectively), but there was no improvement in the MSQoL-54 score (p &amp;gt; 0.05).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: PFEP, which causes a reduction in LUTS by enhancing the MBV of RRMS patients, can be seen as an investment in the future in terms of reducing depression in MS patients and preventing or delaying SD in women.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620664&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2&quot;&gt;33620664&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11255-021-02804-y&gt;10.1007&#x2F;s11255-021-02804-y&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620664&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":56,"discovery_date":"2021-02-24","title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001&#x2F;jama.2020.26858.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;IMPORTANCE: Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease of the central nervous system characterized by inflammatory demyelination with axonal transection. MS affects an estimated 900 000 people in the US. MS typically presents in young adults (mean age of onset, 20-30 years) and can lead to physical disability, cognitive impairment, and decreased quality of life. This review summarizes current evidence regarding diagnosis and treatment of MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBSERVATIONS: MS typically presents in young adults aged 20 to 30 years with unilateral optic neuritis, partial myelitis, sensory disturbances, or brainstem syndromes such as internuclear ophthalmoplegia developing over several days. The prevalence of MS worldwide ranges from 5 to 300 per 100 000 people and increases at higher latitudes. Overall life expectancy is less than in the general population (75.9 vs 83.4 years), and MS more commonly affects women (female to male sex distribution of nearly 3:1). Diagnosis is made based on a combination of signs and symptoms, radiographic findings (eg, magnetic resonance imaging [MRI] T2 lesions), and laboratory findings (eg, cerebrospinal fluid-specific oligoclonal bands), which are components of the 2017 McDonald Criteria. Nine classes of disease-modifying therapies (DMTs), with varying mechanisms of action and routes of administration, are available for relapsing-remitting MS, defined as relapses at onset with stable neurologic disability between episodes, and secondary progressive MS with activity, defined as steadily increasing neurologic disability following a relapsing course with evidence of ongoing inflammatory activity. These drugs include interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribine, and 3 types of monoclonal antibodies. One additional DMT, ocrelizumab, is approved for primary progressive MS. These DMTs reduce clinical relapses and MRI lesions (new T2 lesions, gadolinium-enhancing lesions). Efficacy rates of current DMTs, defined by reduction in annualized relapse rates compared with placebo or active comparators, range from 29%-68%. Adverse effects include infections, bradycardia, heart blocks, macular edema, infusion reactions, injection-site reactions, and secondary autoimmune adverse effects, such as autoimmune thyroid disease.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS AND RELEVANCE: MS is characterized by physical disability, cognitive impairment, and other symptoms that affect quality of life. Treatment with DMT can reduce the annual relapse rate by 29% to 68% compared with placebo or active comparator.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2&quot;&gt;33620411&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1001&#x2F;jama.2020.26858&gt;10.1001&#x2F;jama.2020.26858&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620411&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":55,"discovery_date":"2021-02-24","title":"The Efficacy of Ketogenic Therapies in the Clinical Management of People with Neurodegenerative Disease: A Systematic Review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Adv Nutr. 2021 Feb 23:nmaa180. doi: 10.1093&#x2F;advances&#x2F;nmaa180. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Ketone bodies have potential disease-modifying activity that represent a novel therapeutic approach for neurodegenerative diseases (NDD). The aim of this systematic review was to summarize and evaluate the evidence for the application of ketogenic therapies (dietary or exogenous ketogenic agents) for NDD and provide recommendations for future research. Eight databases were electronically searched for articles reporting on controlled trials (≥4 wk duration) that induced ketosis or elevated serum ketone concentrations in people with NDD. Of 4498 records identified, 17 articles met the inclusion criteria with a total of 979 participants including studies on mild cognitive impairment (MCI; n &#x3D; 6), multiple sclerosis (n &#x3D; 4), Alzheimer&#39;s disease (n &#x3D; 5), Parkinson&#39;s disease (n &#x3D; 1), and MCI secondary to Parkinson&#39;s disease (n &#x3D; 1). Of 17 studies, 7 were randomized double-blind placebo-controlled trials. Most studies used dietary interventions (n &#x3D; 9), followed by medium-chain triglycerides (n &#x3D; 7) and a fasting protocol (n &#x3D; 1). Generally, trials were 6 wk in duration and assessed cognition as the primary outcome. Studies were heterogeneous in type and severity of NDD, interventions used, and outcomes assessed. Overall, 3&#x2F;17 studies carried a low risk of bias. Based on available evidence, exogenous ketogenic agents may be more feasible than dietary interventions in NDD from a compliance and adherence perspective; more research is required to confirm this. Recommendations for future research include improving exogenous formulations to reduce adverse effects, exploring interindividual factors affecting response-to-treatment, and establishing a &quot;minimum required dose&quot; for clinically meaningful improvements in disease-specific symptoms, such as cognition or motor function.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621313&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2&quot;&gt;33621313&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1093&#x2F;advances&#x2F;nmaa180&gt;10.1093&#x2F;advances&#x2F;nmaa180&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621313&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":54,"discovery_date":"2021-02-24","title":"Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Ann Clin Transl Neurol. 2021 Feb 23. doi: 10.1002&#x2F;acn3.51310. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing-remitting multiple sclerosis who had a suboptimal response to previous disease-modifying treatment. The objective of the present study was to assess the safety of shorter OCR infusions in a substudy of CHORDS. After completing four doses of OCR per initial US prescribing recommendations in the main study, participants in the substudy (N &#x3D; 129) received a fifth dose over a 2-h duration (vs. 3.5 h). Infusion-related reactions occurred in 12.4% of patients. None were severe, life-threatening or led to treatment discontinuation. Shorter infusion time did not change the safety profile of OCR. Clinicaltrials.gov (NCT0237856).&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621404&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2&quot;&gt;33621404&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;acn3.51310&gt;10.1002&#x2F;acn3.51310&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33621404&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223200936&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":53,"discovery_date":"2018-11-01","title":"Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: A case report","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Rev Neurol (Paris). 2021 Feb 19:S0035-3787(21)00032-1. doi: 10.1016&#x2F;j.neurol.2020.11.003. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618890&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33618890&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.neurol.2020.11.003&gt;10.1016&#x2F;j.neurol.2020.11.003&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618890&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":52,"discovery_date":"2018-11-01","title":"Diet-dependent regulation of TGFβ impairs reparative innate immune responses after demyelination","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Metab. 2021 Feb;3(2):211-227. doi: 10.1038&#x2F;s42255-021-00341-7. Epub 2021 Feb 18.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Proregenerative responses are required for the restoration of nervous-system functionality in demyelinating diseases such as multiple sclerosis (MS). Yet, the limiting factors responsible for poor CNS repair are only partially understood. Here, we test the impact of a Western diet (WD) on phagocyte function in a mouse model of demyelinating injury that requires microglial innate immune function for a regenerative response to occur. We find that WD feeding triggers an ageing-related, dysfunctional metabolic response that is associated with impaired myelin-debris clearance in microglia, thereby impairing lesion recovery after demyelination. Mechanistically, we detect enhanced transforming growth factor beta (TGFβ) signalling, which suppresses the activation of the liver X receptor (LXR)-regulated genes involved in cholesterol efflux, thereby inhibiting phagocytic clearance of myelin and cholesterol. Blocking TGFβ or promoting triggering receptor expressed on myeloid cells 2 (TREM2) activity restores microglia responsiveness and myelin-debris clearance after demyelinating injury. Thus, we have identified a druggable microglial immune checkpoint mechanism regulating the microglial response to injury that promotes remyelination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33619376&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33619376&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s42255-021-00341-7&gt;10.1038&#x2F;s42255-021-00341-7&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33619376&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":51,"discovery_date":"2018-11-01","title":"Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Elife. 2021 Feb 22;10:e57417. doi: 10.7554&#x2F;eLife.57417.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Cells exist within complex milieus of communicating factors, such as cytokines, that combine to generate context-specific responses, yet nearly all knowledge about the function of each cytokine and the signaling propagated downstream of their recognition is based on the response to individual cytokines. Here, we found that regulatory T cells (Tregs) integrate concurrent signaling initiated by IL-2 and IL-4 to generate a response divergent from the sum of the two pathways in isolation. IL-4 stimulation of STAT6 phosphorylation was blocked by IL-2, while IL-2 and IL-4 synergized to enhance STAT5 phosphorylation, IL-10 production, and the selective proliferation of IL-10-producing Tregs, leading to increased inhibition of conventional T cell activation and the reversal of asthma and multiple sclerosis in mice. These data define a mechanism of combinatorial cytokine signaling and lay the foundation upon which to better understand the origins of cytokine pleiotropy while informing improved the clinical use of cytokines.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33617447&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33617447&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.7554&#x2F;eLife.57417&gt;10.7554&#x2F;eLife.57417&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33617447&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":50,"discovery_date":"2018-11-01","title":"Quantifying upper limb tremor in people with multiple sclerosis using Fast Fourier Transform based analysis of wrist accelerometer signals","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Rehabil Assist Technol Eng. 2021 Feb 3;8:2055668320966955. doi: 10.1177&#x2F;2055668320966955. eCollection 2021 Jan-Dec.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Tremor is a disabling symptom of Multiple Sclerosis (MS). The development of objective methods of tremor characterisation to assess intervention efficacy and disease progression is therefore important. The possibility of using a Fast Fourier Transform (FFT) method for tremor detection was explored.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Acceleration from a wrist-worn device was analysed using FFTs to identify and characterise tremor magnitude and frequency. Processing parameters were explored to provide insight into the optimal algorithm. Participants wore a wrist tri-axial accelerometer during 9 tasks. The FAHN clinical assessment of tremor was used as the reference standard.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Five people with MS and tremor (57.6 ± 15.3 years, 3 F&#x2F;2M) and ten disease-free controls (42.4 ± 10.9 years, 5 M&#x2F;5F) took part. Using specific algorithm settings tremor identification was possible (peak frequency 3-15Hz; magnitude greater than 0.06 g; 2 s windows with 50% overlap; using 2 of 3 axes of acceleration), giving sensitivity 0.974 and specificity 0.971 (38 tremor occurrences out of 108 tasks, 1 false positive, 2 false negatives). Tremor had frequency 3.5-13.0 Hz and amplitude 0.07-2.60g.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Upper limb tremor in people with MS can be detected using a FFT approach based on acceleration recorded at the wrist, demonstrating the possibility of using this minimally encumbering technique within clinical practice.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614109&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33614109&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7869147&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;PMC7869147&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;2055668320966955&gt;10.1177&#x2F;2055668320966955&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614109&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":49,"discovery_date":"2018-11-01","title":"Uncovering New Challenges in Targeting Glycolysis to Treat Th17 Cell-Mediated Autoimmunity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Immunometabolism. 2021;3(1):e210006. doi: 10.20900&#x2F;immunometab20210006. Epub 2021 Jan 22.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Targeting glycolysis in T helper 17 (Th17) cells presents an attractive opportunity to treat Th17 cell-mediated autoimmune diseases such as multiple sclerosis (MS). Pyruvate kinase isoform 2 (PKM2) is a glycolytic enzyme expressed in T cells infiltrating the central nervous system in a mouse model of MS, suggesting PKM2 modulation could provide a new avenue for MS therapeutics. In a recent article in &lt;i&gt;Science Signaling&lt;&#x2F;i&gt;, Seki et al. show that pharmacological modulation of PKM2 alters but does not ameliorate disease in a mouse model of MS. These results warrant further consideration of PKM2 modulators to treat Th17 cell-mediated autoimmunity.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614166&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33614166&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7894650&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;PMC7894650&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.20900&#x2F;immunometab20210006&gt;10.20900&#x2F;immunometab20210006&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614166&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":48,"discovery_date":"2018-11-01","title":"Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102831. doi: 10.1016&#x2F;j.msard.2021.102831. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Spasticity is a common problematic symptom in Multiple Sclerosis with over one third of patients failing first line therapies. Intrathecal baclofen is a safe and efficacious option for treatment resistant spasticity. Anecdotally patients report improved concentration&#x2F;cognitive performance when switching to intrathecal baclofen (ITB) from systemic medications.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIM: To explore whether subjects who proceed with ITB pump implantation for spasticity management and reduce oral anti-spasticity agents will have improved cognitive function.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Subjects were admitted for trial of ITB via lumbar puncture and subsequent pump implantation. Spasticity and cognitive measures before ITB trial and 3 months post implant were recorded. Paired t-test or Wilcoxon Signed Ranks test was used for within subject change and effect sizes (Cohen&#39;s d&lt;sub&gt;z&lt;&#x2F;sub&gt;) were calculated. Subgroup analysis of those on ≥2, or ≤ 1 spasticity medications at baseline was performed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 27 subjects with MS completed per protocol. Mean age 46 years [26 - 56], disease duration 15 years [6 - 26], RRMS &#x3D; 3, SPMS &#x3D; 17 and PPMS&#x3D;7. The majority were on multiple spasticity medications. Spasticity scores significantly improved post pump implant. Mean ITB dose at 3 months was 143 mcg &#x2F; day and 19 discontinued all other treatments for spasticity. There was no deterioration on any cognitive or mood measure. An improvement of moderate effect size was found in Backwards Digit Span (d&#x3D;0.41, p&#x3D;0.059) and HADS - anxiety (d&#x3D;0.37, p&#x3D;0.097). Fatigue Severity Scale score decreased substantially (d&#x3D;0.81, p&#x3D;0.005). Small improvements in Symbol Digit Modalities Test score (d&#x3D;0.24) and Sustained Attention to Response Task response time (d&#x3D;0.23) were non-significant. Performance on other measures did not change. Effect sizes were larger in subgroup on ≥2 oral spasticity medications at baseline, compared to the group on ≤1 medication (SDMT, d&#x3D;0.42 vs d&#x3D;0.07; Backwards digit span 0.45 vs 0.28; HADS-anxiety 0.39 vs 0.32; HADS-depression d&#x3D;0.32 vs 0.05 and FSS, d&#x3D; 1.14 vs 0.42).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: In a pilot study exploring the impact of ITB on cognition, spasticity scores improved universally and beneficial effects on some measures of fatigue, anxiety, auditory attention and verbal working memory were found. Improvement of speed of processing in those withdrawing higher doses of oral medication was also demonstrated suggesting that switching to ITB has added cognitive and psychological benefits for people with MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618123&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33618123&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102831&gt;10.1016&#x2F;j.msard.2021.102831&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618123&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":47,"discovery_date":"2018-11-01","title":"Feasibility and efficacy of a physical activity intervention for managing restless legs syndrome in multiple sclerosis: Results of a pilot randomized controlled trial","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102836. doi: 10.1016&#x2F;j.msard.2021.102836. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: This pilot randomized controlled trial examined the feasibility and efficacy of a physical activity behavior change intervention for improving restless legs syndrome (RLS) severity and secondary sleep outcomes among a sample of adults with multiple sclerosis (MS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Participants with MS(N&#x3D;15) were randomly assigned into intervention(n&#x3D;8) or waitlist control(n&#x3D;7) conditions. The physical activity intervention was delivered over a 16-week period and outcomes were assessed at baseline and immediately following the 16-week period in both conditions.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: There was a significant, positive effect of the intervention on overall RLS severity (p&#x3D;.01;η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.43), severity during the night(p&#x3D;.03,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.35), severity during the day while resting(p&#x3D;.01,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.44), and severity during the day while active(p&amp;lt;.01,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.61), and non-significant improvements in RLS severity while falling asleep (p&#x3D;.33,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.09). There were significant positive effects on sleep satisfaction(p&amp;lt;.01,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.49) and non-significant improvements in self-reported global sleep quality(p&#x3D;.35,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.08). There was a significant intervention effect on self-reported time in bed(p&#x3D;.03,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.37) and total sleep time(p&#x3D;.03,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.36), and non-significant improvements in self-reported sleep latency (p&#x3D;.08,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.25), sleep efficiency(p&#x3D;.27,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.11), and daytime sleepiness (p&#x3D;.52,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.04;p&#x3D;.35,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.08;p&#x3D;.51,η&lt;sub&gt;ρ&lt;&#x2F;sub&gt;&lt;sup&gt;2&lt;&#x2F;sup&gt;&#x3D;.04). There was no significant effect of the intervention on device-measured sleep quality.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: We provide preliminary evidence for the feasibility and efficacy of a physical activity intervention for reducing RLS severity and potentially improving self-reported sleep outcomes in adults with MS. CLINICALTRIALS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;GOV IDENTIFICATION NUMBER: NCT04061681.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618120&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33618120&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102836&gt;10.1016&#x2F;j.msard.2021.102836&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618120&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":46,"discovery_date":"2018-11-01","title":"Design considerations for a multiple sclerosis fatigue mobile app MS Energize: A pragmatic iterative approach using usability testing and resonance checks","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Internet Interv. 2021 Feb 2;24:100371. doi: 10.1016&#x2F;j.invent.2021.100371. eCollection 2021 Apr.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) is a chronic neurological condition affecting around 2.2 million people worldwide. The illness includes a range of symptoms, with fatigue considered to be one of the most disabling. This paper describes how a pragmatic and iterative approach, supported by usability and resonance testing, was used to build a minimum viable product of MS Energize-or MS Energise in UK English regions. MS Energise is a mobile application focused on self-management of fatigue for people with MS. The iterative approach included various stages of testing, during which user feedback including comments about interface, navigation and content, was sought to inform incremental app development and continual improvement. Usability testing was conducted with 11 people with longstanding multiple sclerosis in New Zealand and the United Kingdom, and focused on particular sections of the app as well as the accessibility of the app to users with MS. Two participants contributed to further resonance testing post-release to ensure the app was perceived as relevant and useful to the user. The usability testing and resonance testing phases suggested that user experience of MS Energise was mostly positive. Participants provided a number of suggestions for improvements to aspects of content and design; some of which we implemented during our app development process. Findings will also contribute to future planning and design iteration to enhance the user experience. The next step is further improvement of MS Energise prior to a trial of its clinical and cost effectiveness.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614414&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33614414&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7878181&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;PMC7878181&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.invent.2021.100371&gt;10.1016&#x2F;j.invent.2021.100371&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614414&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":45,"discovery_date":"2018-11-01","title":"Multiple Koenen Tumors, a Rare Entity: Combination Treatment with 1% Topical Sirolimus Electrofulguration and Excision","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Skin Appendage Disord. 2021 Jan;7(1):66-70. doi: 10.1159&#x2F;000511743. Epub 2020 Dec 16.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Koenen tumors are benign, cutaneous manifestations of tuberous sclerosis. These are disfiguring, painful, and challenging to treat as they frequently recur. We report a case of long-standing, multiple Koenen tumors affecting all twenty nails in an elderly female who was successfully treated with a combination of topical sirolimus 1%, surgical excision, and electrofulguration.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CASE REPORT: A 57-year-old lady presented with multiple, asymptomatic periungual, and subungual tumors affecting all twenty nails since 27 years. Cutaneous examination revealed confetti macules, ash-leaf macule, and shagreen patch over trunk. Nail biopsy was compatible with Koenen&#39;s tumor. Computerized tomography of brain showed diffuse patchy sclerosis. The tumors were treated with topical sirolimus 1% ointment for 10 months with excellent regression. Electro-fulguration for both great toenails and surgical excision of right thumbnail periungual fibroma was done. 1% sirolimus was advised after the surgical treatment. There were no adverse effects or recurrence of tumors over a 2-year follow-up.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;DISCUSSION: Topical sirolimus 1% was effective in tumor regression and preventing new tumor formation. Larger tumors that interfered in daily chores were treated with excision and electrofulguration. Thus, a combination treatment for this rare presentation of tuberous sclerosis provided optimum results.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614724&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33614724&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7879313&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;PMC7879313&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1159&#x2F;000511743&gt;10.1159&#x2F;000511743&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33614724&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":44,"discovery_date":"2018-11-01","title":"Management strategies for neurogenic lower urinary tract dysfunction: a qualitative study of the experiences of people with multiple sclerosis and healthcare professionals","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Disabil Rehabil. 2021 Feb 22:1-11. doi: 10.1080&#x2F;09638288.2021.1887378. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: Urinary symptoms are highly prevalent among people with MS. This study aimed to explore the experiences of people with MS and HCPs in managing urinary symptoms and explore their views on using TTNS to treat urinary symptoms.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;MATERIALS AND METHODS: Audio-recorded semi-structured, interviews were employed with people with MS and HCPs. All transcribed interviews were exported to NVivo software (Version 12) and analyzed using a reflexive approach to thematic analysis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Four main themes were identified; The wide-ranging negative impacts of urinary symptoms (&quot;It&#39;s limited everything else&quot;), Gaps in urinary services (&quot;Is there somebody like that, sort of specialized in that area?&quot;), Management strategies (&quot;I don&#39;t go too far from the toilet in case I need to use one&quot;), and optimism about TTNS (&quot;Are you giving Me Hope?&quot;).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Urinary symptoms are common and very troublesome for people with MS. Despite their prevalence, many people with MS continue to suffer in silence. People with MS require skilled multidisciplinary services guided by clinical care pathways to improve service provision and to address urinary symptoms. HCP&#39;s and people with MS are open to the use of TTNS for urinary symptoms and have clear preferences for location and duration of intervention delivery. Implications for rehabilitation Urinary symptoms are very common and troublesome for people with multiple sclerosis, yet many continue to suffer in silence. People with multiple sclerosis lack knowledge about treatment options for urinary symptoms. There is an on-going need for healthcare provider education on guidelines for screening and managing urinary symptoms in people with MS and the role of specialist urinary service providers. HCP&#39;s and people with MS are open to the use of TTNS for urinary symptoms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33617371&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33617371&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1080&#x2F;09638288.2021.1887378&gt;10.1080&#x2F;09638288.2021.1887378&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33617371&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":43,"discovery_date":"2018-11-01","title":"Physician Compensation in the United States - Through the Lens of the MS Neurologist","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 17;50:102847. doi: 10.1016&#x2F;j.msard.2021.102847. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE OF REVIEW: To explore the elements that are typically considered when determining physician compensation in the United States and to examine if the compensation of neurologists with expertise in multiple sclerosis (MS) care is commensurate with that for other neurological specialists and medical specialists that also employ complex therapies, e.g., oncology.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RECENT FINDINGS: The complexity in the diagnosis and management of MS requires increasing specialization. Additionally, changing models for the delivery of MS care has resulted in the MS neurologist generating significant contribution margins. In fact, the revenue to compensation ratio for the MS neurologist may be significantly higher than that of any other discipline in neuroscience service lines. However, while the contribution margin is often a key justification of compensation of interventional and intensive care practitioners in neuroscience service lines, it is generally not considered in the MS neurologist&#39;s compensation. Compensation models for MS neurologists typically depend heavily on the absolute number of relative value units associated with evaluation and management (E&amp;amp;M) codes making other fields of neurology financially more attractive to trainees.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;SUMMARY: In considering the shortage of MS specialists, the demands of their discipline, and the revenue to compensation ratios, the MS neurologist is significantly undercompensated relative to other neurological specialists and to physicians in other disciplines. Compensating the MS neurologist appropriately and supporting the necessary infrastructure for MS care will likely attract more trainees to this discipline and help reverse the current scarcity of MS neurologists in the United States.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618121&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33618121&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102847&gt;10.1016&#x2F;j.msard.2021.102847&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618121&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":42,"discovery_date":"2018-11-01","title":"Role of extracellular vesicles in neurodegenerative diseases","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Prog Neurobiol. 2021 Feb 19:102022. doi: 10.1016&#x2F;j.pneurobio.2021.102022. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Extracellular vesicles (EVs) are heterogeneous cell-derived membranous structures that arise from the endosome system or directly detach from the plasma membrane. In recent years, many advances have been made in the understanding of the clinical definition and pathogenesis of neurodegenerative diseases, but translation into effective treatments is hampered by several factors. Current research indicates that EVs are involved in the pathology of diseases such as Alzheimer&#39;s disease (AD), Parkinson&#39;s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington&#39;s disease (HD). Besides, EVs are also involved in the process of myelin formation, and can also cross the blood-brain barrier to reach the sites of CNS injury. It is suggested that EVs have great potential as a novel therapy for the treatment of neurodegenerative diseases. Here, we reviewed the advances in understanding the role of EVs in neurodegenerative diseases and addressed the critical function of EVs in the CNS. We have also outlined the physiological mechanisms of EVs in myelin regeneration and highlighted the therapeutic potential of EVs in neurodegenerative diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33617919&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33617919&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.pneurobio.2021.102022&gt;10.1016&#x2F;j.pneurobio.2021.102022&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33617919&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":41,"discovery_date":"2018-11-01","title":"Emerging Therapeutic Applications for Fumarates","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Trends Pharmacol Sci. 2021 Feb 19:S0165-6147(21)00007-9. doi: 10.1016&#x2F;j.tips.2021.01.004. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Fumarates are successfully used for the treatment of psoriasis and multiple sclerosis. Their antioxidative, immunomodulatory, and neuroprotective properties make fumarates attractive therapeutic candidates for other pathologies. The exact working mechanisms of fumarates are, however, not fully understood. Further elucidation of the mechanisms is required if these drugs are to be successfully repurposed for other diseases. Towards this, administration route, dosage, and treatment timing, frequency, and duration are important parameters to consider and optimize with clinical paradigms in mind. Here, we summarize the rapidly expanding literature on the pharmacokinetics and pharmacodynamics of fumarates, including a discussion on two recently FDA-approved fumarates Vumerity&lt;sup&gt;TM&lt;&#x2F;sup&gt; and Bafiertam&lt;sup&gt;TM&lt;&#x2F;sup&gt;. We review emerging applications of fumarates, focusing on neurological and cardiovascular diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618840&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33618840&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.tips.2021.01.004&gt;10.1016&#x2F;j.tips.2021.01.004&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33618840&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":40,"discovery_date":"2018-11-01","title":"The Novel Coronavirus Infection (COVID-19) and Nervous System Involvement: Mechanisms of Neurological Disorders, Clinical Manifestations, and the Organization of Neurological Care","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurosci Behav Physiol. 2021 Feb 18:1-8. doi: 10.1007&#x2F;s11055-021-01050-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The new coronavirus SARS-CoV-2 and the disease it causes COVID-19 involves not only respiratory system damage, but can also lead to disorders of the central and peripheral nervous system, as well as the muscular system. This article presents published data and our own observations on the course of neurological disorders in COVID-19 patients. There is a relationship between the severity of COVID-19 and the severity and frequency of neurological manifestations. Severe neurological disorders are mostly seen in severe cases of COVID-19 and include acute cerebrovascular accidents (aCVA), acute necrotizing encephalopathy, and Guillain-Barré syndrome. Factors potentially complicating the course of COVID-19 and increasing the development of neurological complications include arterial hypertension, diabetes mellitus, and chronic cardiac and respiratory system diseases. Questions of the possible effects of human coronaviruses on the course of chronic progressive neurological diseases are addressed using multiple sclerosis (MS) as an example. We discuss the management of patients with aCVA and MS depending on the risk of developing coronavirus infection.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33619413&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33619413&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7889305&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;PMC7889305&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s11055-021-01050-0&gt;10.1007&#x2F;s11055-021-01050-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33619413&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":39,"discovery_date":"2018-11-01","title":"Activated microglia drive demyelination via CSF1R signaling","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Glia. 2021 Feb 23. doi: 10.1002&#x2F;glia.23980. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Microgliosis is a prominent pathological feature in many neurological diseases including multiple sclerosis (MS), a progressive auto-immune demyelinating disorder. The precise role of microglia, parenchymal central nervous system (CNS) macrophages, during demyelination, and the relative contributions of peripheral macrophages are incompletely understood. Classical markers used to identify microglia do not reliably discriminate between microglia and peripheral macrophages, confounding analyses. Here, we use a genetic fate mapping strategy to identify microglia as predominant responders and key effectors of demyelination in the cuprizone (CUP) model. Colony-stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor (M-CSF) - a secreted cytokine that regulates microglia development and survival-is upregulated in demyelinated white matter lesions. Depletion of microglia with the CSF1R inhibitor PLX3397 greatly abrogates the demyelination, loss of oligodendrocytes, and reactive astrocytosis that results from CUP treatment. Electron microscopy (EM) and serial block face imaging show myelin sheaths remain intact in CUP treated mice depleted of microglia. However, these CUP-damaged myelin sheaths are lost and robustly phagocytosed upon-repopulation of microglia. Direct injection of CSF1 into CNS white matter induces focal microgliosis and demyelination indicating active CSF1 signaling can promote demyelination. Finally, mice defective in adopting a toxic astrocyte phenotype that is driven by microglia nevertheless demyelinate normally upon CUP treatment implicating microglia rather than astrocytes as the primary drivers of CUP-mediated demyelination. Together, these studies indicate activated microglia are required for and can drive demyelination directly and implicate CSF1 signaling in these events.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620118&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2&quot;&gt;33620118&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1002&#x2F;glia.23980&gt;10.1002&#x2F;glia.23980&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33620118&#x2F;?utm_source&#x3D;Chrome&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210223163220&amp;v&#x3D;2.14.2","published_date":"","source":"","relevant":null,"table_constraints":null},{"article_id":38,"discovery_date":"2018-11-01","title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 11;50:102842. doi: 10.1016&#x2F;j.msard.2021.102842. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Natalizumab (NTZ) treatment of multiple sclerosis (MS) has been associated with increased risk of progressive multifocal leukoencephalopathy (PML). The aim of the present study was to evaluate the impact of PML risk assessment on PML incidence in NTZ treated MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: By using information from the population-based Swedish MS registry a retrospective cohort was established of patients treated with NTZ between 2006-2018. The effect on PML incidence before and after utilizing a risk management plan, including JC virus (JCV) serology, was analyzed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In December 2018, 804 PML cases associated with NTZ therapy of MS had been reported globally, including 9 cases from Sweden. The estimated PML incidence 2018 in Sweden and globally was 0.7 (0.3-1.4) and 4.15 (3.9-4.4) per 1,000 person years, respectively. In Sweden, JCV serology was introduced 2012 for PML risk assessment and the cumulative risk of PML was significantly lower 2012-2018 compared to the period 2006-2011 (p&#x3D;0.042). The mean NTZ exposure time was 60.1 months (SD 37.2) in the first period (2006-2011) and 32.6 months (SD 22.0) in the second period (2012-2018). The number of patients treated with NTZ decreased, and the number of patients at increased risk of PML was 1.9 % at the end of the study period.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Since 2006 the incidence of PML associated with NTZ treatment of MS has decreased in Sweden. Our findings suggest that this reduction is due to an effective adoptation and adherence to the established risk management plan that implies switching patients at increased PML risk from NTZ to other highly efficacious therapies. A less pronounced decline in PML incidence has recently been observed in France, but not globally.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33610957&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102842&gt;10.1016&#x2F;j.msard.2021.102842&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":37,"discovery_date":"2018-11-01","title":"Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroinflammation. 2021 Feb 20;18(1):52. doi: 10.1186&#x2F;s12974-021-02102-5.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Tissue plasminogen activator (tPA) is a serine protease involved in fibrinolysis. It is released by endothelial cells, but also expressed by neurons and glial cells in the central nervous system (CNS). Interestingly, this enzyme also contributes to pathological processes in the CNS such as neuroinflammation by activating microglia and increasing blood-brain barrier permeability. Nevertheless, its role in the control of adaptive and innate immune response remains poorly understood.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: tPA effects on myeloid and lymphoid cell response were studied in vivo in the mouse model of multiple sclerosis experimental autoimmune encephalomyelitis and in vitro in splenocytes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: tPA&lt;sup&gt;-&#x2F;-&lt;&#x2F;sup&gt; animals exhibited less severe experimental autoimmune encephalomyelitis than their wild-type counterparts. This was accompanied by a reduction in both lymphoid and myeloid cell populations in the spinal cord parenchyma. In parallel, tPA increased T cell activation and proliferation, as well as cytokine production by a protease-dependent mechanism and via plasmin generation. In addition, tPA directly raised the expression of MHC-II and the co-stimulatory molecules CD80 and CD86 at the surface of dendritic cells and macrophages by a direct action dependent of the activation of epidermal growth factor receptor.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Our study provides new insights into the mechanisms responsible for the harmful functions of tPA in multiple sclerosis and its animal models: tPA promotes the proliferation and activation of both lymphoid and myeloid populations by distinct, though complementary, mechanisms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33610187&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s12974-021-02102-5&gt;10.1186&#x2F;s12974-021-02102-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":36,"discovery_date":"2018-11-01","title":"Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007&#x2F;s00415-021-10460-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Previous studies have reported an association between anti-tumor necrosis factor alpha (anti-TNFα) treatment and central nervous system (CNS) events. We described eight patients presenting with demyelinating CNS events while on treatment with anti-TNFα for autoimmune diseases and followed up for a medium period of 4 years. Four patients presented with isolated demyelinating events, three patients fulfilled the criteria for multiple sclerosis (MS), and one patient showed worsening of pre-existing MS after anti-TNF therapy initiation. All patients except one, showed a good medium-term prognosis. Our observation supports an association between anti-TNFα treatment and demyelinating events and suggests that a prompt discontinuation of the drug may lead to a favorable demyelinating disease outcome.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611609&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10460-6&gt;10.1007&#x2F;s00415-021-10460-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":35,"discovery_date":"2018-11-01","title":"Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 21. doi: 10.1007&#x2F;s00415-021-10436-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) and functional neurological disorder (FND) are both diagnostically challenging conditions which can present with similar symptoms. We systematically reviewed the literature to identify patients with MS who were misdiagnosed with FND, patients with FND who were misdiagnosed with MS, and reports of patients with both conditions. In addition to FND, we included studies of patients with other functional and psychiatric disorders where these caused symptoms leading to investigation for or a diagnosis of MS, which in a different context would likely have been labeled as FND. Our review suggests that MS is one of the most common causes of misdiagnosis of FND and vice versa. We discuss the clinical errors that appear to result in misdiagnoses, such as over-reliance on psychiatric comorbidity when making a diagnosis of FND or over-reliance on neuroimaging for the diagnosis of MS, and practical ways to avoid them. Comorbidity between these two conditions is also likely common, has been poorly studied, and adds complexity to diagnosis and treatment in patients with both MS and FND. Misdiagnosis and comorbidity in a landscape of emerging evidence-based treatments for both MS and FND are issues not only of clinical importance to the care of these patients, but also to treatment trials, especially of MS, where FND could be a hidden confounder.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611631&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611631&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10436-6&gt;10.1007&#x2F;s00415-021-10436-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611631&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":34,"discovery_date":"2018-11-01","title":"COVID-19 in multiple sclerosis patients treated with dimethyl fumarate","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007&#x2F;s00415-021-10446-4. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611610&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611610&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10446-4&gt;10.1007&#x2F;s00415-021-10446-4&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611610&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":33,"discovery_date":"2018-11-01","title":"Efficacy of Gamma Knife radiosurgery in the management of multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurosurg Rev. 2021 Feb 20. doi: 10.1007&#x2F;s10143-021-01507-3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Trigeminal neuralgia (TN) is the most frequent craniofacial pain condition, which commonly affects patients suffering from multiple sclerosis (MS). Stereotactic radiosurgery, especially Gamma Knife radiosurgery (GKRS), represents a safe and effective treatment for TN, and it has been adopted also for MS-TN, with a lower success rate. Therefore, we aimed to analyze the outcome of GKRS for MS-TN. PubMed, Web of Science, and Google Scholar and the reference list of relevant articles were searched for GKRS in MS-TN. Two investigators independently identified the articles, assessed the study quality, and extracted the data. Endpoints of interest were initial pain responders, successful treatments at the end of follow-up, and factors influencing the outcome. Data analyses were performed using R software. Twelve articles involving 646 patients met our inclusion criteria. Pooled proportion of patients who experienced an initial response to GKRS treatment was 83% (CI 74-90%). The cumulative proportion of successful treatments at the end of follow-up was 47% (CI 33-60%). No variables were found to have a significant contribution to heterogeneity regarding the initial response outcome. The only variable significantly explaining the heterogeneity found in the proportion of successful treatments was the length of the follow-up, with a negative b coefficient (- 0.0051, p value &#x3D; 0.0047). Regarding the efficacy of GKRS in MS-TN, the initial pain response rate was 83%, which dramatically decreases to 47% during follow-up. GKRS still represents a valuable option for MS-TN; however, its long-term efficacy should be always considered.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611721&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611721&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10143-021-01507-3&gt;10.1007&#x2F;s10143-021-01507-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611721&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":32,"discovery_date":"2018-11-01","title":"Blood Trace Element Status in Multiple Sclerosis: a Systematic Review and Meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Biol Trace Elem Res. 2021 Feb 21. doi: 10.1007&#x2F;s12011-021-02621-5. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The aim of this meta-analysis was to investigate whether the blood concentrations of patients with multiple sclerosis (MS) are associated with those of the healthy control group in terms of trace elements including zinc (Zn), iron (Fe), manganese (Mn), magnesium (Mg), selenium (Se), and copper (Cu). A comprehensive search was performed in online databases including PubMed, Scopus, Embase, and Web of Science for studies, which have addressed trace elements in MS up to July 23, 2020. The chi-square test and I&lt;sup&gt;2&lt;&#x2F;sup&gt; statistic were utilized to evaluate inter-study heterogeneity across the included studies. Weighted mean differences (WMDs) and corresponding 95% CI were considered as a pooled effect size (ES). Twenty-seven articles (or 32 studies) with a total sample comprised of 2895 participants (MS patients (n &#x3D; 1567) and controls (n &#x3D; 1328)) were included. Pooled results using random-effects model indicated that the levels of Zn (WMD &#x3D; - 7.83 mcg&#x2F;dl, 95% CI &#x3D; - 12.78 to - 2.87, Z &#x3D; 3.09, P &#x3D; 0.002), and Fe (WMD &#x3D; - 13.66 mcg&#x2F;dl, 95% CI &#x3D; - 23.13 to - 4.19, Z &#x3D; 2.83, P &#x3D; 0.005) were significantly lower in MS patients than in controls. However, it was found that levels of Mn (WMD &#x3D; 0.03 mcg&#x2F;dl, 95% CI &#x3D; 0.01 to 0.04, Z &#x3D; 2.89, P &#x3D; 0.004) were significantly higher in MS patients. Yet, no significant differences were observed in the levels of Mg, Se, and Cu between both groups. This meta-analysis revealed that the circulating levels of Zn and Fe were significantly lower in MS patients and that Mn level was significantly higher than those in the control group. However, it was found that there was no significant difference between MS patients and controls with regard to levels of Mg, Se, and Cu.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611740&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611740&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s12011-021-02621-5&gt;10.1007&#x2F;s12011-021-02621-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611740&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":31,"discovery_date":"2018-11-01","title":"Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Feb 19:10.1212&#x2F;WNL.0000000000011630. doi: 10.1212&#x2F;WNL.0000000000011630. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a two-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statistics.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Genetic variants in the vicinity of &lt;i&gt;TNFRSF1A&lt;&#x2F;i&gt;, the gene encoding TNF receptor 1 (TNFR1), were identified as predictive of pharmacologic blockade of TNFR1 signaling by anti-TNF therapy, based on genetic associations with lower circulating C-reactive protein (CRP; GWAS N &#x3D; 204,402). The effects of TNF-TNFR1 inhibition were estimated for PD risk (N&lt;sub&gt;cases&lt;&#x2F;sub&gt;&#x2F;&lt;sub&gt;controls&lt;&#x2F;sub&gt; &#x3D; 37,688&#x2F;981,372) and age at PD onset (N &#x3D; 28,568) using GWAS data from the International Parkinson&#39;s Disease Genomics Consortium and 23andMe, Inc. To validate variants as proxies of long-term anti-TNF treatment, we also assessed whether variant associations reflected anticipated effects of TNFR1 inhibition on Crohn disease, ulcerative colitis and multiple sclerosis risk (N &#x3D; 38,589-45,975).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: TNF-TNFR1 signaling inhibition was not estimated to affect PD risk (odds ratio&#x2F;OR per 10% lower circulating CRP &#x3D; 0.99; 95% CI: 0.91-1.08) or age at onset (0.13 years later onset; 95% CI: -0.66 to 0.92). In contrast, genetically-indexed TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease (OR &#x3D; 0.75; 95% CI: 0.65-0.86) and ulcerative colitis (OR &#x3D; 0.84; 95% CI: 0.74-0.97) and increased multiple sclerosis risk (OR &#x3D; 1.57; 95% CI: 1.36-1.81). Findings were consistent across models using different genetic instruments and MR estimators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Our findings do not imply that TNF-TNFR1 signaling inhibition will prevent or delay PD onset.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that TNF-TNFR1 signaling inhibition is not associated with the risk or age at onset of PD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608417&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33608417&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011630&gt;10.1212&#x2F;WNL.0000000000011630&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608417&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":30,"discovery_date":"2018-11-01","title":"Sexual dimorphism in immunometabolism and autoimmunity: Impact on personalized medicine","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102775. doi: 10.1016&#x2F;j.autrev.2021.102775. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Immune cells play essential roles in metabolic homeostasis and thus, undergo analogous changes in normal physiology (e.g., puberty and pregnancy) and in various metabolic and immune diseases. An essential component of this close relationship between the two is sex differences. Many autoimmune diseases, such as systemic lupus erythematous and multiple sclerosis, feature strikingly increased prevalence in females, whereas in contrast, infectious diseases, such as Ebola and Middle East Respiratory Syndrome, affect more men than women. Therefore, there are fundamental aspects of metabolic homeostasis and immune functions that are regulated differently in males and females. This can be observed in sex hormone-immune interaction where androgens, such as testosterone, have shown immunosuppressive effects whilst estrogen is on the opposite side of the spectrum with immunoenhancing facilitation of mechanisms. In addition, the two sexes exhibit significant differences in metabolic regulation, with estrous cycles in females known to induce variability in traits and more pronounced metabolic disease phenotype exhibited by males. It is likely that these differences underlie both the development of metabolic and autoimmune diseases and the response to current treatment options. Sexual dimorphism in immunometabolism has emerged to become an area of intense research, aiming to uncover sex-biased effector molecules in the various metabolic tissues and immune cell types, identify sex-biased cell-type-specific functions of common effector molecules, and understand whether the sex differences in metabolic and immune functions influence each other during autoimmune pathogenesis. In this review, we will summarize recent findings that address these critical questions of sexual dimorphism in immunometabolism as well as their translational implications for the clinical management of autoimmune diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609790&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609790&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.autrev.2021.102775&gt;10.1016&#x2F;j.autrev.2021.102775&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609790&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":29,"discovery_date":"2018-11-01","title":"Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007&#x2F;s00415-021-10466-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609155&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609155&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10466-0&gt;10.1007&#x2F;s00415-021-10466-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609155&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":28,"discovery_date":"2018-11-01","title":"Menopause does not modify disability trajectories in a longitudinal cohort of women with CIS and MS followed from disease onset","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Feb 20. doi: 10.1111&#x2F;ene.14782. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: to evaluate the effect of menopause on disability accumulation in women followed from their clinically isolated syndrome (CIS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We examined the longitudinal changes in EDSS from CIS until the last follow-up in women belonging to the Barcelona CIS prospective cohort, followed through their menopausal transition. The analysis is based on 13,718 EDSS measurements with an average of 28 EDSS per patient. Differences in EDSS trajectories between menopausal and non-menopausal women, controlling for age and disease duration were evaluated. We performed two sensitivity analyses, in women with confirmed MS and in those experiencing and early menopause.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: from 764 eligible women, 496 (65%) responded to the questionnaire and 74 (14.9%) reached menopause over follow-up. We did not find a significant inflection point in EDSS trajectories around menopause (slope change -0.009 (95%CI -0.066; 0.046). The annual increase in EDSS over the complete course of the disease was significantly higher in menopausal women (0.049 IC 95% 0.026 - 0.074) versus non-menopausal (0.019 IC 95% 0.008 - 0.031, interaction p-value 0.025). This difference was lost once controlling for age and disease duration (EDSS annual increase of 0.059 95% CI 0.025- 0.094 vs 0.038 IC 95% 0.021 - 0.057 respectively, interaction p-value 0.321). No inflection point was detected when the analysis was restricted to women with confirmed MS or with earlier menopause.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: menopause is not associated with an increased risk of disability in a CIS population, considering EDSS trajectories throughout the course of the disease, together with age and disease duration.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609298&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609298&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ene.14782&gt;10.1111&#x2F;ene.14782&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609298&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":27,"discovery_date":"2018-11-01","title":"Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Hosp Pharm. 2021 Mar;28(2):112-114. doi: 10.1136&#x2F;ejhpharm-2019-002048. Epub 2019 Oct 16.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A descriptive retrospective observational study including all patients with RRMS treated with natalizumab followed-up after 10 years.The likelihood of developing PML was estimated based on three risk factors: anti-John Cunningham virus antibody index, previous immunosuppressive therapy, and duration of treatment. Patients were classified into five categories: minimum probability (&amp;lt;0.1&#x2F;1000); low (0.1&#x2F;1000); medium-low (0.2-0.6&#x2F;1000); medium-high (0.8-3&#x2F;1000); high probability (3-10&#x2F;1000).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 34 patients were included. The probability of PML in the last cycle was: 55.9% minimum, 8.8% low, 11.8% medium-low, 3% medium-high, and 20.5% high. 12 patients continue with active treatment with natalizumab. No cases of PML have been confirmed. Adverse effects were detected in 50% of patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Quantifying risk factors allows us to estimate the probability of PML appearance, thus assessing the maintenance or suspension of natalizumab.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608441&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33608441&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;ejhpharm-2019-002048&gt;10.1136&#x2F;ejhpharm-2019-002048&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608441&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":26,"discovery_date":"2018-11-01","title":"Microglial phagocytosis of neurons in neurodegeneration, and its regulation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurochem. 2021 Feb 20. doi: 10.1111&#x2F;jnc.15327. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;There is growing evidence that excessive microglial phagocytosis of neurons and synapses contributes to multiple brain pathologies. RNA-seq and genome wide association (GWAS) studies have linked multiple phagocytic genes to neurodegenerative diseases, and knock-out of phagocytic genes has been found to protect against neurodegeneration in animal models, suggesting that excessive microglial phagocytosis contributes to neurodegeneration. Here, we review recent evidence that microglial phagocytosis of live neurons and synapses causes neurodegeneration in animal models of Alzheimer&#39;s disease and other tauopathies, Parkinson&#39;s disease, frontotemporal dementias, multiple sclerosis, retinal degeneration, and neurodegeneration induced by ischaemia, infection or ageing. We also review factors regulating microglial phagocytosis of neurons, including: nucleotides, frackalkine, phosphatidylserine, calreticulin, UDP, CD47, sialylation, complement, galectin-3, Apolipoprotein E, phagocytic receptors, Siglec receptors, cytokines, microglial epigenetics and expression profile. Some of these factors may be potential treatment targets to prevent neurodegeneration mediated by excessive microglial phagocytosis of live neurons and synapses.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608912&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33608912&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;jnc.15327&gt;10.1111&#x2F;jnc.15327&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608912&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":25,"discovery_date":"2018-11-01","title":"B lymphocytes, the gastrointestinal tract and autoimmunity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102777. doi: 10.1016&#x2F;j.autrev.2021.102777. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Under homeostatic conditions, bidirectional interactions between the gastrointestinal and the immune system allow production of both inflammatory and anti-inflammatory responses designed to prevent undesirable inflammation and to respond efficiently to potential insults. This balanced regulation can be disrupted in disorders that affect tissues remote to the gastrointestinal tract, as seen in autoimmune diseases. Recent reports have described a variety of B lymphocyte-mediated functions that likely contribute to gastrointestinal homeostasis to a greater extent than previously thought. Studies have shown that early B cell development takes place within the intestine, and that self-reactive B cells are rendered tolerant using mechanisms known to occur in the bone marrow, indicating that the gastrointestinal tract contributes to maintaining immune tolerance to self. Relatedly, continuous bacterial stimulation is essential for maintaining regulatory B cell functions and for mediating mucosal homeostasis. In studies of neuro-inflammation, intestinal IgA+ B cells, which constitute a prominent source of lymphocytes in the organism, can migrate to inflamed tissues and exert regulatory functions that attenuate inflammation in the central nervous system, indicating that, in addition to its local effects in the intestin, gut microbiota-B cell crosstalk can exert long-range beneficial effects. At the translational level, metabolites produced by gut microbiota can act as B cell-intrinsic epigenetic modulators, reducing inflammation in the skin and kidneys of mice suffering from experimental lupus. Given the significant impact of B cell-intestinal microbiota interactions, there is a momentum for improving our understanding of these pathways in autoinflammatory diseases and for designing novel therapeutic strategies for systemic autoimmune diseases where B cells play key roles.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609796&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.autrev.2021.102777&gt;10.1016&#x2F;j.autrev.2021.102777&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":24,"discovery_date":"2018-11-01","title":"Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 3;50:102807. doi: 10.1016&#x2F;j.msard.2021.102807. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Studies on the prevalence of neuromyelitis optica spectrum disorder (NMOSD) are still scarce. The aim of the current study was to determine the prevalence rate of NMOSD in Belo Horizonte, southeast Brazil, where the prevalence rate of multiple sclerosis (MS) has already been established.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: For this observational study, eligible patients had to meet the 2015 International Panel for Neuromyelitis Optica Diagnosis, be seen at the study center between January 2000 and February 2019 and live in Belo Horizonte. The prevalence rate of NMOSD was estimated based on the number of MS and NMOSD patients seen at same Center during the same period, and the previously established prevalence of MS in Belo Horizonte.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: During the study period, there were 69 patients with NMOSD, 60 (87.0%) of whom were females, and 44 (63.8%) non-whites. The median age at disease onset was 36.7 (4-72) years, the mean EDSS score 4.78±2.36, and the mean ARR 0.57±0.43. Anti-aquaporin-4 immunoglobulin testing was available for 61 (88.4%) patients, of whom 41 (67.2%) had a positive result. During the same period, 280 MS patients were seen. Considering the local known prevalence rate of MS of 18.1&#x2F;100,000 inhabitants, the estimated NMOSD prevalence rate in Belo Horizonte was 4.52&#x2F;100,000 (95% CI 3.72-5.43) inhabitants.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The prevalence rate of NMOSD in Belo Horizonte is high as compared with those found in most of the studies reported to date.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609926&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609926&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102807&gt;10.1016&#x2F;j.msard.2021.102807&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609926&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":23,"discovery_date":"2018-11-01","title":"Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102834. doi: 10.1016&#x2F;j.msard.2021.102834. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disorder; and leads to the uncontrolled production of interleukin (IL)-1β. Multiple sclerosis (MS) is an inflammatory disease of the central nervous system; and its development seems to be partly correlated with IL-1β levels. It is hypothesized that FMF could be associated with MS. We aim to describe the features of patients displaying both diseases and to investigate the MEFV mutation rate in MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Patients with definite MS were retrieved from the cohort of FMF patients in the Reference Center for Rare Auto-inflammatory Diseases and Amyloidosis (CEREMAIA). We also performed a systematic literature review of articles from PubMed that were published from 1990 to 2020.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Twenty-four patients were included in the case series: five patients (1.3%) from our cohort of 364 and 19 patients from the literature. The sex ratio was 2:1. The mean age at diagnosis of FMF was 19 years old; and that for MS was 29 years old. Seven studies investigating the MEFV mutation rate in MS patients were included. Three studies found a higher mutation rate in MS patients than in the control group.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: FMF and MS features were comparable to those of patients with unrelated diseases; and MEFV mutation carriage was not positively correlated with MS. However; MS prevalence in FMF patients was higher than was expected in a healthy population. To a lesser extent; FMF prevalence in MS patients was higher than expected in a healthy population and the difference might not be significant. These data suggest that FMF could be associated with MS; and further studies are needed to investigate a potential causal association.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609923&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609923&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102834&gt;10.1016&#x2F;j.msard.2021.102834&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609923&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":22,"discovery_date":"2018-11-01","title":"Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 13;49:102754. doi: 10.1016&#x2F;j.msard.2021.102754. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Coronavirus disease 2019 (COVID-19) raises particular concerns for people with multiple sclerosis (PwMS) on disease-modifying treatments (DMTs), and for physicians caring for them. The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on PwMS receiving DMTs that inhibit immune cell trafficking, such as natalizumab (NTZ) and fingolimod (FTY), remains to be determined, as do the possible effects of these drugs on both the infection and the related disease.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIMS: To describe self-reported COVID-19 symptoms and disease severity in PwMS on NTZ or FTY who received serology confirmation of SARS-CoV-2 infection.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: From 27th April to 3rd May 2020, telephone interviews were conducted with 140 PwMS under treatment with NTZ or FTY in order to collect structured data on multiple sclerosis (MS) and COVID-19. The patients, all followed at our center, were classified as symptomatic, paucisymptomatic or asymptomatic on the basis of their self-reported clinical characteristics. COVID-19 severity was rated on a 7-point ordinal scale. In addition, in the period 4th May to 3rd June 2020 SARS-CoV-2 serology testing, using the Roche SARS-CoV-2 IgG assay (Elecsys&lt;sup&gt;Ⓡ&lt;&#x2F;sup&gt;), was performed in 104&#x2F;140 (74.2%) of the interviewed PwMS (50 treated with NTZ and 54 with FTY).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 14&#x2F;104 (13.4%) PwMS on NTZ or FTY had anti-SARS-CoV-2 antibodies: 8 met the criteria for asymptomatic, 3 for paucisymptomatic and 3 for symptomatic COVID-19 (COVID-19 severity score lower than 3). None of them required hospitalization or showed severe COVID-19 complications.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Despite the relatively high SARS CoV-2 seroprevalence found in this sample of PwMS, all the positive cases showed either no or only mild COVID-19 symptoms. These reassuring findings indicate a lack of COVID-19 complications in PwMS on DMTs and support the hypothesis that it is safe to maintain ongoing treatment with these drugs in the current setting.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609958&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102754&gt;10.1016&#x2F;j.msard.2021.102754&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":21,"discovery_date":"2018-11-01","title":"Generation of six induced pluripotent stem cell lines from patients with amyotrophic lateral sclerosis with associated genetic mutations in either FUS or ANXA11","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Stem Cell Res. 2021 Feb 12;52:102246. doi: 10.1016&#x2F;j.scr.2021.102246. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of upper and lower motor neurons, causing gradual paralysis, and resulting in death 3-5 years from diagnosis. ALS causative mutations have been identified in multiple genes, including Fused in sarcoma (FUS), and recently characterized Annexin A11 (ANXA11). We have derived induced pluripotent stem cell (iPSC) lines from six ALS patient lymphoblastoid cell lines, three with mutations in FUS (Q519E, R521H, R522G), and three with mutations in ANXA11 (G38R, D40G, R235Q). These lines have been characterized and provide a novel resource for investigation into ALS pathology.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610019&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33610019&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.scr.2021.102246&gt;10.1016&#x2F;j.scr.2021.102246&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610019&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":20,"discovery_date":"2018-11-01","title":"Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102838. doi: 10.1016&#x2F;j.msard.2021.102838. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;There is not much awareness of varicella zoster virus (VZV) associated central nervous system (CNS) infections under treatment with natalizumab. Here we describe two natalizumab treated MS patients who developed acute retinal necrosis combined with CNS vasculitis caused by VZV. In natalizumab treated patients, visual symptoms atypical of optic neuritis should be promptly evaluated by an ophthalmologist. Currently, a total of 12 cases of natalizumab-associated VZV CNS or retinal infections are reported in literature. Our two cases and overview of currently available data provide information on prognosis and treatment decisions of this rare but devastating complication.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609925&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609925&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102838&gt;10.1016&#x2F;j.msard.2021.102838&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609925&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":19,"discovery_date":"2018-11-01","title":"Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2020 Dec 28;49:102724. doi: 10.1016&#x2F;j.msard.2020.102724. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The Expanded Disability Status Scale (EDSS) measures disease progression in Multiple Sclerosis (MS). EDSS changes are assumed to be due to worsening MS-related disability. Strict interpretation of this premise may include some normal findings as abnormal, inflating the disability score. Further, determining the cause of neurologic symptoms can be difficult in an older population with comorbid illness and polypharmacy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To examine the association between EDSS, age, comorbidities and polypharmacy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: 106 people, 55 years and older, with and without MS were administered the EDSS and a validated comorbidity questionnaire. Polypharmacy was also assessed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Median EDSS scores were 6.0 in people with MS and 3.0 in people without MS. No participant in our cohort had an EDSS of 0. Higher EDSS scores were associated with older age and more polypharmacy. Pyramidal and cerebellar functional systems accounted for the largest percentage of unique variance between groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Older individuals with and without MS demonstrated significant disability on the EDSS. These findings indicate that EDSS scores may be partially due to factors other than MS. Our understanding of disease course and disability may benefit from the development of normative EDSS scores to correct for these factors.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609959&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609959&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2020.102724&gt;10.1016&#x2F;j.msard.2020.102724&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609959&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":18,"discovery_date":"2018-11-01","title":"Perilesional neurodegenerative injury in multiple sclerosis: Relation to focal lesions and impact on disability","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 5;49:102738. doi: 10.1016&#x2F;j.msard.2021.102738. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Axonal injury is the primary source of irreversible neurological decline in persons with multiple sclerosis (pwMS). Identifying and quantifying myelin and axonal loss in lesional and perilesional tissue in vivo is fundamental for a better understanding of multiple sclerosis (MS) outcomes and patient impairment. Using advanced magnetic resonance imaging (MRI) methods, consisting of selective inversion recovery quantitative magnetization transfer imaging (SIR-qMT) and multi-compartment diffusion MRI with the spherical mean technique (SMT), we conducted a cross-sectional pilot study to assess myelin and axonal damage in the normal appearing white matter (NAWM) surrounding chronic black holes (cBHs) and how this pathology correlates with disability in vivo. We hypothesized that lesional axonal transection propagates tissue injury in the surrounding NAWM and that the degree of this injury is related to patient disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Eighteen pwMS underwent a 3.0 Tesla conventional clinical MRI, inclusive of T1 and T2 weighted protocols, as well as SIR-qMT and SMT. Regions of interests (ROIs) were manually delineated in cBHs, NAWM neighboring cBHs (perilesional NAWM), distant ipsilateral NAWM and contra-lateral distant NAWM. SIR-qMT-derived macromolecular-to-free pool size ratio (PSR) and SMT-derived apparent axonal volume fraction (V&lt;sub&gt;ax&lt;&#x2F;sub&gt;) were extracted to infer on myelin and axonal content, respectively. Group differences were assessed using mixed-effects regression models and correlation analyses were obtained by bootstrapping 95% confidence interval.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In comparison to perilesional NAWM, both PSR and V&lt;sub&gt;ax&lt;&#x2F;sub&gt; values were reduced in cBHs (p &amp;lt; 0.0001) and increased in distant contra-lateral NAWM ROIs (p &amp;lt; 0.001 for PSR and p &amp;lt; 0.0001 for V&lt;sub&gt;ax&lt;&#x2F;sub&gt;) but not ipsilateral NAWM (p &#x3D; 0.176 for PSR and p &#x3D; 0.549 for V&lt;sub&gt;ax&lt;&#x2F;sub&gt;). V&lt;sub&gt;ax&lt;&#x2F;sub&gt; values measured in cBHs correlated with those in perilesional NAWM (Pearson rho &#x3D; 0.63, p &amp;lt; 0.001). No statistically relevant associations were seen between PSR&#x2F;V&lt;sub&gt;ax&lt;&#x2F;sub&gt; values and clinical and&#x2F;or MRI metrics of the disease with the exception of cBH PSR values, which correlated with the Expanded Disability Status Scale (Pearson rho &#x3D; -0.63, p &#x3D; 0.03).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Our results show that myelin and axonal content, detected by PSR and V&lt;sub&gt;ax&lt;&#x2F;sub&gt;, are reduced in perilesional NAWM, as a function of the degree of focal cBH axonal injury. This finding is indicative of an ongoing anterograde&#x2F;retrograde degeneration and suggests that treatment prevention of cBH development is a key factor for preserving NAWM integrity in surrounding tissue. It also suggests that measuring changes in perilesional areas over time may be a useful measure of outcome for proof-of-concept clinical trials on neuroprotection and repair. PSR and V&lt;sub&gt;ax&lt;&#x2F;sub&gt; largely failed to capture associations with clinical and MRI characteristics, likely as a result of the small sample size and cross-sectional design, however, longitudinal assessment of a larger cohort may unravel the impact of this pathology on disease progression.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609957&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102738&gt;10.1016&#x2F;j.msard.2021.102738&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":17,"discovery_date":"2018-11-01","title":"Disruption of brainstem monoaminergic fibre tracts in multiple sclerosis as a putative mechanism for cognitive fatigue: a fixel-based analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroimage Clin. 2021 Feb 12;30:102587. doi: 10.1016&#x2F;j.nicl.2021.102587. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In multiple sclerosis (MS), monoaminergic systems are altered as a result of both inflammation-dependent reduced synthesis and direct structural damage. Aberrant monoaminergic neurotransmission is increasingly considered a major contributor to fatigue pathophysiology. In this study, we aimed to compare the integrity of the monoaminergic white matter fibre tracts projecting from brainstem nuclei in a group of patients with MS (n &#x3D; 68) and healthy controls (n &#x3D; 34), and to investigate its association with fatigue. Fibre tracts integrity was assessed with the novel fixel-based analysis that simultaneously estimates axonal density, by means of &#39;fibre density&#39;, and white matter atrophy, by means of fibre &#39;cross section&#39;. We focused on ventral tegmental area, locus coeruleus, and raphe nuclei as the main source of dopaminergic, noradrenergic, and serotoninergic fibres within the brainstem, respectively. Fourteen tracts of interest projecting from these brainstem nuclei were reconstructed using diffusion tractography, and compared by means of the product of fibre-density and cross-section (FDC). Finally, correlations of monoaminergic axonal damage with the modified fatigue impact scale scores were evaluated in MS. Fixel-based analysis revealed significant axonal damage - as measured by FDC reduction - within selective monoaminergic fibre-tracts projecting from brainstem nuclei in MS patients, in comparison to healthy controls; particularly within the dopaminergic-mesolimbic pathway, the noradrenergic-projections to prefrontal cortex, and serotoninergic-projections to cerebellum. Moreover, we observed significant correlations between severity of cognitive fatigue and axonal damage within the mesocorticolimbic tracts projecting from ventral tegmental area, as well as within the locus coeruleus projections to prefrontal cortex, suggesting a potential contribution of dopaminergic and noradrenergic pathways to central fatigue in MS. Our findings support the hypothesis that axonal damage along monoaminergic pathways contributes to the reduction&#x2F;dysfunction of monoamines in MS and add new information on the mechanisms by which monoaminergic systems contribute to MS pathogenesis and fatigue. This supports the need for further research into monoamines as therapeutic targets aiming to combat and alleviate fatigue in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33610097&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nicl.2021.102587&gt;10.1016&#x2F;j.nicl.2021.102587&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":16,"discovery_date":"2021-02-20T00:00:00.000Z","title":"ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases - PubMed","summary":"Current strategies for the treatment of demyelinating diseases such as multiple sclerosis (MS) are based on anti-inflammatory or immunomodulatory drugs. Those drugs have the potential to reduce the frequency of new lesions but do not directly promote remyelination in the damaged central nervous system (CNS). Targeting CXCR7 (ACKR3) has been postulated as a potential therapeutic approach in demyelinating diseases, leading to both immunomodulation by reducing leukocyte infiltrates and promyelination by enhancing myelin repair. ACT-1004-1239 is a potent, selective, insurmountable, and orally available first-in-class CXCR7 receptor antagonist. The effect of ACT-1004-1239 was evaluated in the myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) and the cuprizone-induced demyelination mouse models. In addition, ACT-1004-1239 was assessed in a rat oligodendrocyte precursor cell (OPC) differentiation assay in vitro. In the MOG-induced EAE model, ACT-1004-1239 treatment (10-100 mg&#x2F;kg, twice daily, orally) showed a significant dose-dependent reduction in disease clinical scores, resulting in increased survival. At the highest dose tested (100 mg&#x2F;kg, twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltrates into the CNS and plasma neurofilament light chain concentration. Treatment with ACT-1004-1239 dose-dependently increased plasma CXCL12 concentration, which correlated with a reduction of the cumulative disease score. Furthermore, in the cuprizone model, ACT-1004-1239 treatment significantly increased the number of mature myelinating oligodendrocytes and enhanced myelination in vivo. In vitro, ACT-1004-1239 promoted the maturation of OPCs into myelinating oligodendrocytes. These results provide evidence that ACT-1004-1239 both reduces neuroinflammation and enhances myelin repair substantiating the rationale to explore its therapeutic potential in a clinical setting.","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33595155&#x2F;","published_date":"2021-02-20T00:00:00.000Z","source":"FASEB","relevant":1,"table_constraints":null},{"article_id":15,"discovery_date":"2018-11-01","title":"First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 19. doi: 10.1007&#x2F;s00415-021-10469-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Peripapillary retinal nerve fiber layer thickness correlates with radiological and clinical parameters in patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The aim of this study is to investigate the use of the first measured pRNFL thickness as a predictor of disease course in patients with RRMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: One hundred and thirty seven RRMS patients were enrolled in the study within the first 5 years of illness. Patients were followed for 34.1 months and the EDSS was used to assess disability status to determine whether the first measured pRNFL thickness, using proportional hazards models, predicts the risk of disability worsening.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The mean disease duration was 26.1 months. Disability worsening was detected in 36 patients. In tertile-based groups formed according to pRNFL thickness, the group with the lowest pRNFL thickness had a 2.8-fold increase in the risk of disability worsening compared to the group with the highest. The risk was higher in the first 2 years of the study (HR &#x3D; 3.48; p &#x3D; 0.008).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The first measured pRNFL thickness in RRMS patients can predict the risk of disability worsening, and the risk of disability worsening in the early period was higher in the group with the lowest pRNFL value.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606071&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33606071&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10469-x&gt;10.1007&#x2F;s00415-021-10469-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606071&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":14,"discovery_date":"2018-11-01","title":"Healthcare access experiences of persons with MS explored through the Candidacy Framework","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Health Soc Care Community. 2021 Feb 19. doi: 10.1111&#x2F;hsc.13320. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Canada has one of the highest rates of multiple sclerosis (MS) in the world, affecting 1 in every 385 individuals. This neurodegenerative condition is unpredictable and variable in symptom profile and disease course making it difficult to manage. Canadians with MS are high users of healthcare services; however, they report multiple unmet needs, high disease burden, and low satisfaction with healthcare. Access to healthcare is vital to health maintenance and may explain these poor experiences. Access is often measured using utilisation as a proxy, which may fail to capture the complexities of access experiences that this population faces. The Candidacy Framework offers an alternative to utilisation measures, by examining the process of accessing care, while considering the impact of social patterning and health system environments on this process. The aim of the current study is to align the experiences of persons with MS in accessing healthcare services with the stages of the Candidacy Framework. Forty-eight individuals with MS living across Ontario were recruited to participate in one of five focus groups or ten individual interviews. Analysis included a first inductive phase, using constant comparative methods, followed by a deductive phase, using content analysis. The Candidacy Framework was not able to capture all experiences shared by persons with MS, including patient-centred care, past experiences and outcome expectation, and care outcomes. We propose these concepts be included as refinements to the current Framework, providing a more thorough explanation of the experiences of persons with MS in accessing care to manage their condition.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33606904&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;hsc.13320&gt;10.1111&#x2F;hsc.13320&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":13,"discovery_date":"2018-11-01","title":"Hidradenitis suppurativa - The role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Med Hypotheses. 2021 Feb 10;149:110530. doi: 10.1016&#x2F;j.mehy.2021.110530. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Hidradenitis Suppurativa (HS) is a chronic, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. The pathophysiology of the disease remains elusive, with newer therapies targeting various aspects of the dysregulated immune system. This presents a useful opportunity to look at the cytokine profile in HS and other inflammatory conditions that share similar patterns with the aim of teasing out less considered explanations for HS pathogenesis. It has been observed that IL-17 appears to be the most common denominator linking HS with other immune mediated diseases like Crohn, ulcerative colitis, multiple sclerosis and psoriasis. Given that IL-17 plays an important role in antifungal immunity, evidenced by the cytokine pattern in fungal disease and the bulk of data citing their potential involvement in Crohn, ulcerative colitis, multiple sclerosis and psoriasis; it is fair to suggest the need to explore the role that fungi play in the setting of HS going forward. The aryl hydrocarbon receptor (ahr) is a ubiquitous and largely conserved entity that is gaining interest in inflammatory conditions such as psoriasis and atopic dermatitis. It is well known to modulate autoimmune states. Its activation by both exogenous and endogenous agents result in secretion of IL-17 by Th17 cells. One of such agents is the tryptophan metabolite 6-formylindolo [3,2-b] carbazole (FICZ)-which can be produced by microorganisms such as fungi. It will be interesting to explore its usefulness in HS pathogenesis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607406&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33607406&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.mehy.2021.110530&gt;10.1016&#x2F;j.mehy.2021.110530&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607406&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":12,"discovery_date":"2018-11-01","title":"Depression and multiple sclerosis: A bidirectional Mendelian randomisation study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177&#x2F;1352458521996601. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Depression is common in multiple sclerosis (MS); however, the underlying mechanism for the relationship remains unknown. In this study, we examined a putative causal relationship between depression and MS using a bidirectional Mendelian randomisation (MR) framework. Using the latest genome-wide association study data available, 168 non-major histocompatibility complex (MHC) independent variants associated with MS and 96 independent genetic variants associated with depression susceptibility were used. Maximum likelihood, weighted median, inverse variance weighted method and MR-Egger regression analyses were performed. There was no significant risk for the development of MS in persons carrying variants associated with depression or for risk of depression in individuals who are genetically susceptible to MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605804&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33605804&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521996601&gt;10.1177&#x2F;1352458521996601&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605804&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":11,"discovery_date":"2018-11-01","title":"The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177&#x2F;1352458521995484. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Obesity is associated with increased risk of multiple sclerosis (MS); however, the underlying mechanisms remain unclear.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To determine the extent to which decreased vitamin D bioavailability and altered levels of adiponectin and leptin mediate the association between obesity and MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We performed Mendelian randomization (MR) analyses to estimate the effects on MS of body mass index (BMI), 25-hydroxyvitamin D (25OHD), adiponectin, and leptin levels in a cohort of 14,802 MS cases and 26,703 controls. We then estimated the proportion of the effect of obesity on MS explained by these potential mediators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Genetic predisposition to higher BMI was associated with increased MS risk (odds ratio (OR) &#x3D; 1.33 per standard deviation (SD), 95% confidence interval (CI) &#x3D; 1.09-1.63), while higher 25OHD levels reduced odds of MS (OR &#x3D; 0.72 per SD, 95% CI &#x3D; 0.60-0.87). In contrast, we observed no effect of adiponectin or leptin. In MR mediation analysis, 5.2% of the association between BMI and MS was attributed to obesity lowering 25OHD levels (95% CI &#x3D; 0.3%-31.0%).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: This study found that a minority of the increased risk of MS conferred by obesity is mediated by lowered vitamin D levels, while leptin and adiponectin had no effect. Consequently, vitamin D supplementation would only modestly reverse the effect of obesity on MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33605807&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521995484&gt;10.1177&#x2F;1352458521995484&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":10,"discovery_date":"2018-11-01","title":"N-Acetyl-Lysyltyrosylcysteine Amide, a Novel Systems Pharmacology Agent, Reduces Bronchopulmonary Dysplasia in Hyperoxic Neonatal Rat Pups","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Free Radic Biol Med. 2021 Feb 16:S0891-5849(21)00079-4. doi: 10.1016&#x2F;j.freeradbiomed.2021.02.006. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Bronchopulmonary dysplasia (BPD) is caused primarily by oxidative stress and inflammation. To induce BPD, neonatal rat pups were raised in hyperoxic (&amp;gt;90% O&lt;sub&gt;2&lt;&#x2F;sub&gt;) environments from day one (P1) until day ten (P10) and treated with N-acetyl-lysyltyrosylcysteine amide (KYC). In vivo studies showed that KYC improved lung complexity, reduced myeloperoxidase (MPO) positive (+) myeloid cell counts, MPO protein, chlorotyrosine formation, increased endothelial cell CD31 expression, decreased 8-OH-dG and Cox-1&#x2F;Cox-2, HMGB1, RAGE, TLR4, increased weight gain and improved survival in hyperoxic pups. EPR studies confirmed that MPO reaction mixtures oxidized KYC to a KYC thiyl radical. Adding recombinant HMGB1 to the MPO reaction mixture containing KYC resulted in KYC thiylation of HMGB1. In rat lung microvascular endothelial cell (RLMVEC) cultures, KYC thiylation of RLMVEC proteins was increased the most in RLMVEC cultures treated with MPO+H&lt;sub&gt;2&lt;&#x2F;sub&gt;O&lt;sub&gt;2&lt;&#x2F;sub&gt;, followed by H&lt;sub&gt;2&lt;&#x2F;sub&gt;O&lt;sub&gt;2&lt;&#x2F;sub&gt;, and then KYC alone. KYC treatment of hyperoxic pups decreased total HMGB1 in lung lysates, increased KYC thiylation of HMGB1, terminal HMGB1 thiol oxidation, decreased HMGB1 association with TLR4 and RAGE, and shifted HMGB1 in lung lysates from a non-acetylated to a lysyl-acetylated isoform, suggesting that KYC reduced lung cell death and that recruited immune cells had become the primary source of HMGB1 released into the hyperoxic lungs. MPO-dependent and independent KYC-thiylation of Keap1 were both increased in RLMVEC cultures. Treating hyperoxic pups with KYC increased KYC thiylation and S-glutathionylation of Keap1, and Nrf2 activation. These data suggest that KYC is a novel system pharmacological agent that exploits MPO to inhibit toxic oxidant production and is oxidized into a thiyl radical that inactivates HMGB1, activates Nrf2, and increases antioxidant enzyme expression to improve lung complexity and reduce BPD in hyperoxic rat pups.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607217&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33607217&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.freeradbiomed.2021.02.006&gt;10.1016&#x2F;j.freeradbiomed.2021.02.006&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607217&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":9,"discovery_date":"2018-11-01","title":"CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 18;11(1):4132. doi: 10.1038&#x2F;s41598-021-83591-5.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;To identify markers in the CSF of multiple sclerosis (MS) subtypes, we used a two-step proteomic approach: (i) Discovery proteomics compared 169 pooled CSF from MS subtypes and inflammatory&#x2F;degenerative CNS diseases (NMO spectrum and Alzheimer disease) and healthy controls. (ii) Next, 299 proteins selected by comprehensive statistics were quantified in 170 individual CSF samples. (iii) Genes of the identified proteins were also screened among transcripts in 73 MS brain lesions compared to 25 control brains. F-test based feature selection resulted in 8 proteins differentiating the MS subtypes, and secondary progressive (SP)MS was the most different also from controls. Genes of 7 out these 8 proteins were present in MS brain lesions: GOLM was significantly differentially expressed in active, chronic active, inactive and remyelinating lesions, FRZB in active and chronic active lesions, and SELENBP1 in inactive lesions. Volcano maps of normalized proteins in the different disease groups also indicated the highest amount of altered proteins in SPMS. Apolipoprotein C-I, apolipoprotein A-II, augurin, receptor-type tyrosine-protein phosphatase gamma, and trypsin-1 were upregulated in the CSF of MS subtypes compared to controls. This CSF profile and associated brain lesion spectrum highlight non-inflammatory mechanisms in differentiating CNS diseases and MS subtypes and the uniqueness of SPMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603109&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603109&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41598-021-83591-5&gt;10.1038&#x2F;s41598-021-83591-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603109&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":8,"discovery_date":"2018-11-01","title":"Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Neurosci. 2021 Feb 18. doi: 10.1038&#x2F;s41593-021-00801-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegeneration occurring in multiple sclerosis (MS) contributes to the progression of disability. It is therefore important to identify and neutralize the mechanisms that promote neurodegeneration in MS. Here, we report that oxidized phosphatidylcholines (OxPCs) found in MS lesions, previously identified as end-product markers of oxidative stress, are potent drivers of neurodegeneration. Cultured neurons and oligodendrocytes were killed by OxPCs, and this was ameliorated by microglia. After OxPC injection, mouse spinal cords developed focal demyelinating lesions with prominent axonal loss. The depletion of microglia that accumulated in OxPC lesions exacerbated neurodegeneration. Single-cell RNA sequencing of lesioned spinal cords identified unique subsets of TREM2&lt;sup&gt;high&lt;&#x2F;sup&gt; mouse microglia responding to OxPC deposition. TREM2 was detected in human MS lesions, and TREM2&lt;sup&gt;-&#x2F;-&lt;&#x2F;sup&gt; mice exhibited worsened OxPC lesions. These results identify OxPCs as potent neurotoxins and suggest that enhancing microglia-mediated OxPC clearance via TREM2 could help prevent neurodegeneration in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603230&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603230&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41593-021-00801-z&gt;10.1038&#x2F;s41593-021-00801-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603230&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":7,"discovery_date":"2018-11-01","title":"Binocular Vision in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Optom (Auckl). 2021 Feb 12;13:39-49. doi: 10.2147&#x2F;OPTO.S286862. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: Oculomotor disorders have been reported in multiple sclerosis (MS) in up to 80% of cases. There have been studies evaluating binocular vision in several neurological diseases, but not in MS. Considering that a high percentage of eye-movement anomalies have been reported, the aim of this study was to analyze binocular vision in these subjects.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A total of 59 participants with MS - 21 with monocular optic neuritis, eleven with binocular optic neuritis, and 27 without optic neuritis - and 26 age-matched controls were enrolled. Binocular vision was analyzed using near point of convergence (NPC), positive and negative fusional vergence for far and near distance, measurement of heterophoria at both distances with cover and modified Thorington tests, and random-dot stereoscopy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The percentage of subjects with abnormal NPC values was highest in the MS group, followed by the MSONm (MS with optic neuritis in one eye), MSONb (MS with optic neuritis in both eyes), and control groups. MS patients showed an esophoric trend at near distance. Positive fusional vergence showed no significant differences between control and MS groups, but higher variability in recovery was found in MS groups. Negative fusional vergence at near distance showed significant differences between the control group and the two MS groups, with optic neuritis for both break-point and recovery values. A high percentage of patients with MS had alterations on stereopsis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Alterations in binocular vision were present in MS, with divergence at near distance and stereopsis the most affected parameters. Likewise, MS patients with optic neuritis showed worse binocular vision.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603529&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603529&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7886387&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7886387&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2147&#x2F;OPTO.S286862&gt;10.2147&#x2F;OPTO.S286862&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603529&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":6,"discovery_date":"2018-11-01","title":"The Therapeutic Targets of Fingolimod (FTY720) Are Involved in Pathological Processes in the Frontal Cortex of Alzheimer&#39;s Disease Patients: A Network Pharmacology Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Aging Neurosci. 2021 Feb 2;13:609679. doi: 10.3389&#x2F;fnagi.2021.609679. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; The sphingosine-1-phosphate receptor (S1PR) modulator fingolimod (FTY720), which is commonly used as an immunomodulator in multiple sclerosis treatment, has recently been found to reduce pathological changes in the brain tissue of Alzheimer&#39;s disease (AD) animal models, but this has yet to be verified in human brain tissue. In this study, network pharmacology methods were applied to determine the potential pharmacological mechanisms of fingolimod in the frontal cortex of AD patients. &lt;b&gt;Methods:&lt;&#x2F;b&gt; The pharmacological macromolecular targets of fingolimod and fingolimod phosphate were downloaded from SwissTarget and DrugBank. Systematic intersection analysis of the expression profiles of brain frontal cortex tissues (423 AD tissues and 266 control tissues) was performed to obtain AD-associated fingolimod targets (F-ADGs). Immune cell infiltration analysis and a primary mouse cortical culture RNA-seq drug screen database were used to identify immune-related F-ADGs and cortex-related F-ADGs. Then, the expression values of F-ADGs were correlated with the disease severity score (MMSE score) of AD patients to identify severity-related F-ADGs. We also analyzed miRNA expression microarray data in the frontal cortex of AD patients associated with disease severity to obtain severity-related F-ADG-miRNAs. &lt;b&gt;Results:&lt;&#x2F;b&gt; A total of 188 F-ADGs were detected in the frontal cortices of AD patients and were enriched in biological processes such as synaptic signaling, inflammatory response, and response to oxygen-containing compounds. Eleven immune-related F-ADGs (like FPR1, BLNK.) and 17 cortex-related F-ADGs (like ALDH1L1, DUSP1.) were detected. Other F-ADGs, such as S1PR1 and GABBR2, although not classified into the above two categories, were still predicted by bioinformatics methods to play an important role in the development of AD. Two F-ADGs (GNAQ and MMP14) and 28 miRNAs (like miR- 323a-3p, miR-181a-5p.) were found to be associated with AD severity (MMSE 0-27 group). Fifteen F-ADGs (like ALDH1L1, FPR1, and IL6.) and 46 miRNAs (like miR-212-5p, miR-93-5p.) were found to be associated with mild or moderate dementia AD patients&#39; severity (MMSE11-22 subgroup). &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Fingolimod may affect the brain frontal cortex function of AD patients in many different ways, such as affecting immune cell infiltration, nerve cell, or glial cell function, and synaptic function. miRNAs may also be involved. ALDH1L1, FPR1, S1PR1, and GABBR2 may be core drug targets.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603656&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603656&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7884771&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7884771&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fnagi.2021.609679&gt;10.3389&#x2F;fnagi.2021.609679&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603656&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":5,"discovery_date":"2018-11-01","title":"Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Can J Infect Dis Med Microbiol. 2021 Jan 31;2021:6616763. doi: 10.1155&#x2F;2021&#x2F;6616763. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract infection (UTI) and posttreatment improvement of urinary tract symptoms in patients with relapsing-remitting multiple sclerosis. This double-blind randomized clinical trial was conducted on 56 people with multiple sclerosis relapse who had undergone methylprednisolone for 5 days. Patients were randomly split into two groups: oral prednisolone and placebo (tapering for 20 days). Demographic data, duration of multiple sclerosis, urinary tract symptoms, the Expanded Disability Status Scale (EDSS) score, and urine data were analyzed. The incidence of UTI in the intervention and control groups did not differ significantly (&lt;i&gt;p&lt;&#x2F;i&gt;&#x3D;560). However, the improvement of urinary tract symptoms in the intervention group was significantly more favorable than in the control group (&lt;i&gt;p&lt;&#x2F;i&gt; ≤ 0.001). Furthermore, administering OPT after IVMP did not increase the risk of UTI occurrence in patients with multiple sclerosis exacerbation. The urine analysis results did not show any differences at baseline and after the corticosteroid tapering regimen. Due to the risk of infection by corticosteroids, it is no longer necessary to do further urinary screening in this group of patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603936&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603936&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7870309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7870309&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1155&#x2F;2021&#x2F;6616763&gt;10.1155&#x2F;2021&#x2F;6616763&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603936&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":4,"discovery_date":"2018-11-01","title":"Rare Case of Spinal Neurosarcoidosis with Concomitant Epidural Lipomatosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Case Rep Neurol Med. 2021 Jan 28;2021:5952724. doi: 10.1155&#x2F;2021&#x2F;5952724. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Spinal neurosarcoidosis is a rare disease that can manifest as myelopathy, radiculopathy, or cauda equine syndrome. Spinal epidural lipomatosis is also a rare condition resulting from overgrowth of epidural fat tissue causing compressive myelopathy. To our knowledge, there are no reports linking epidural lipomatosis and spinal neurosarcoidosis. &lt;i&gt;Case Report&lt;&#x2F;i&gt;. We describe a case of progressive myelitis in the presence of concomitant spinal neurosarcoidosis and epidural lipomatosis which was a challenging diagnosis with complete response to treatment after addressing both diseases. Both etiologies are inflammatory in nature and share similar expression of inflammatory factors such as TNF-&lt;i&gt;α&lt;&#x2F;i&gt; and IL-1&lt;i&gt;β&lt;&#x2F;i&gt;.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The common inflammatory process involved in these two diseases might explain a pathophysiological interconnection between both diseases that may underlie their concomitant development in our patient. If these two diseases are interconnected, in their pathophysiological mechanism remains a hypothesis that will need further investigation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33604089&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33604089&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7869444&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7869444&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1155&#x2F;2021&#x2F;5952724&gt;10.1155&#x2F;2021&#x2F;5952724&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33604089&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":3,"discovery_date":"2018-11-01","title":"Patient Satisfaction With the Quality of Counseling Provided by Advanced Practice Nurses Specialized in Multiple Sclerosis: A Quantitative Analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurosci Nurs. 2021 Feb 17. doi: 10.1097&#x2F;JNN.0000000000000578. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The challenges in dealing with multiple sclerosis (MS) have increased considerably in recent years. In addition to neurologists, MS nurse specialists are key to the management of MS patients, but there is a lack of evidence regarding their quality of counseling. METHODS: The data collection took place between October 2018 and March 2019 in the outpatient clinic of a university hospital. The quality of counseling was assessed using the APN-BQ, an instrument that contains 19 items that can be assigned to 4 dimensions. Participants were asked to rate their satisfaction on a scale from 0 to 3. General satisfaction was assessed on a scale from 0 to 100. RESULTS: The participants (n &#x3D; 110) rated the quality of counseling and their general satisfaction high. The mean (SD) of the structure quality dimension was 2.64 (0.44), and satisfaction with length and frequency of consultations (2.53 [0.63]) scored better than outcome quality (1.99 [0.62]) and process quality (2.13 [0.60]). CONCLUSION: Overall, there was a high rate of satisfaction with the quality of counseling. In addition to the length and frequency of consultations, MS patients particularly appreciated the availability and expertise of MS nurse specialists.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605649&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33605649&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;JNN.0000000000000578&gt;10.1097&#x2F;JNN.0000000000000578&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605649&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":2,"discovery_date":"2018-11-01","title":"Is Migraine Associated to Brain Anatomical Alterations? New Data and Coordinate-Based Meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Topogr. 2021 Feb 19. doi: 10.1007&#x2F;s10548-021-00824-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;A growing number of studies investigate brain anatomy in migraine using voxel- (VBM) and surface-based morphometry (SBM), as well as diffusion tensor imaging (DTI). The purpose of this article is to identify consistent patterns of anatomical alterations associated with migraine. First, 19 migraineurs without aura and 19 healthy participants were included in a brain imaging study. T1-weighted MRIs and DTI sequences were acquired and analyzed using VBM, SBM and tract-based spatial statistics. No significant alterations of gray matter (GM) volume, cortical thickness, cortical gyrification, sulcus depth and white-matter tract integrity could be observed. However, migraineurs displayed decreased white matter (WM) volume in the left superior longitudinal fasciculus. Second, a systematic review of the literature employing VBM, SBM and DTI was conducted to investigate brain anatomy in migraine. Meta-analysis was performed using Seed-based d Mapping via permutation of subject images (SDM-PSI) on GM volume, WM volume and cortical thickness data. Alterations of GM volume, WM volume, cortical thickness or white-matter tract integrity were reported in 72%, 50%, 56% and 33% of published studies respectively. Spatial distribution and direction of the disclosed effects were highly inconsistent across studies. The SDM-PSI analysis revealed neither significant decrease nor significant increase of GM volume, WM volume or cortical thickness in migraine. Overall there is to this day no strong evidence of specific brain anatomical alterations reliably associated to migraine. Possible explanations of this conflicting literature are discussed. Trial registration number: NCT02791997, registrated February 6th, 2015.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606142&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33606142&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10548-021-00824-6&gt;10.1007&#x2F;s10548-021-00824-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606142&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":1,"discovery_date":"2018-11-01","title":"COVID-19, HHV6 and MOG antibody: A perfect storm","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 12;353:577521. doi: 10.1016&#x2F;j.jneuroim.2021.577521. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Serious neurological complications of SARS-CoV-2 are increasingly being recognized.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CASE: We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienced complete neurological recovery with gancyclovir, high dose corticosteroids, and plasma exchange. To our knowledge, this is the first case of HHV6 reactivation in the central nervous system in the setting of COVID19 infection and the first case of MOG-IgG myelitis in the setting of SARS-CoV-2 and HHV6 coinfection.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients with neurological manifestations in the setting of COVID19-related immunodeficiency should be tested for opportunistic infections including HHV6. Viral infection is a known trigger for MOG-IgG and therefore this antibody should be checked in patients with SARS-CoV-2 associated demyelination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607505&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33607505&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577521&gt;10.1016&#x2F;j.jneuroim.2021.577521&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607505&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null}]